WO2019225948A1 - Patch for alleviation and prevention of acne - Google Patents

Patch for alleviation and prevention of acne Download PDF

Info

Publication number
WO2019225948A1
WO2019225948A1 PCT/KR2019/006068 KR2019006068W WO2019225948A1 WO 2019225948 A1 WO2019225948 A1 WO 2019225948A1 KR 2019006068 W KR2019006068 W KR 2019006068W WO 2019225948 A1 WO2019225948 A1 WO 2019225948A1
Authority
WO
WIPO (PCT)
Prior art keywords
acne
patch
metal
prevention
biodegradable metal
Prior art date
Application number
PCT/KR2019/006068
Other languages
French (fr)
Korean (ko)
Inventor
조성윤
Original Assignee
랩앤피플주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190058730A external-priority patent/KR102310566B1/en
Application filed by 랩앤피플주식회사 filed Critical 랩앤피플주식회사
Priority to BR112020023541-5A priority Critical patent/BR112020023541B1/en
Priority to CN201980033618.9A priority patent/CN112135609B/en
Priority to US17/057,103 priority patent/US11679085B2/en
Priority to ES19807769T priority patent/ES2966155T3/en
Priority to EP19807769.5A priority patent/EP3782615B1/en
Priority to JP2020564559A priority patent/JP7317863B2/en
Publication of WO2019225948A1 publication Critical patent/WO2019225948A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • the present invention relates to a patch for alleviating and preventing acne, and more particularly, to a new use of a biodegradable metal containing magnesium as a main component.
  • microneedles were proposed in 1998 by the Frausnits Group of Georgia Institute of Technology to make microneedle arrays of silicon devices using semiconductor process technology.
  • the microneedles When the microneedles are inserted into the skin, the microneedles must maintain a sufficiently high physical strength so that the microneedles can be inserted without being bent or broken.
  • stainless steel was used as the material of the microneedle, but inflammation occurred when small particles remained in the body, and polymers (PLA, PGA, and biodegradable copolymer) were used. There was a problem of not being penetration.
  • Korean Unexamined Patent Publication No. 2016-0058261 is a water-soluble microorganism based on polyglycolide (PGA), polylactide-glycolide copolymer (PLGA), hyaluronic acid, alginic acid, pectin and the like.
  • a needle and a manufacturing method thereof are disclosed, and
  • Korean Patent No. 1622388 discloses a silicon micro needle stamp and a manufacturing method thereof, and
  • Korean Patent Publication No. 2015-0121053 discloses a silicon, silicon dioxide, ceramic, metal (stainless steel, titanium, Nickel, molybdenum, chromium, cobalt and the like) and synthetic or natural resins have been disclosed for microneedle coated with Japanese encephalitis vaccine antigen.
  • the microneedle up to now is an alternative drug administration means that can replace the drug delivery method through oral administration or injection method, and penetrates the epidermis without stimulating pain sensory nerves distributed in the skin. It has been used as a device capable of delivering drugs, a kind of drug carrier.
  • Korean Patent Application Publication No. 2017-0115449 previously filed by the present applicant, discloses a microneedle using a biodegradable metal and a patch including the same. It has been confirmed that the effect is also expressed in wrinkle improvement.
  • the present invention seeks to provide a novel use of biodegradable metals, which are the main component of microneedles that have been developed as conventional drug delivery means.
  • the present invention is confirmed that the biodegradable metal itself, which was used as a main component of the microneedle, expresses antimicrobial activity against acne causing bacteria, and does not include a separate drug. We want to provide a new use.
  • the present invention is a biodegradable metal represented by the formula (1), and has an anti acne bacterium effect, provides a patch for acne relief and prevention.
  • X is the one or more selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P.
  • the biodegradable metal may be included in the form of microneedles or in the form of a thin plate.
  • the biodegradable metal may be Mg of 95% or more pure purity including inevitable impurities.
  • the biodegradable metal may be one or more metal phases to generate a galvanic circuit to accelerate the decomposition rate.
  • Such biodegradable metal may be one comprising an Mg 2 Ca phase, one comprising an MgZn phase, or one comprising a Ca 2 Mg 6 Zn 3 phase.
  • the biodegradable metal may be coated with a second kind of second metal on the metal surface to form a galvanic circuit.
  • the second metal is selected from the group consisting of sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold, manganese and calcium It may be one or more metals.
  • Another embodiment of the present invention provides a method for attaching and using the aforementioned acne relief and prevention patch on acne skin.
  • the water supply step or the skin soothing step may be performed before the acne relief and prevention patch is attached to the acne skin.
  • the patch to which the biodegradable metal of the present invention is applied is useful for alleviating and preventing acne by having antimicrobial activity against acne causing bacteria on its own, without the need for a separate drug, and by using a simple method of applying it to the skin by making it in various forms. You can prevent acne or relieve the acne caused.
  • FIG. 1 is an exploded view of microneedles in which microneedles are processed into sheets composed of biodegradable metals.
  • FIG. 2 is a schematic view of a microneedle bent over the processed microneedles.
  • FIG 3 is a schematic view of a microneedle and microneedle holder in the form of a tip.
  • FIG. 4 is a prototype (A) of the microneedle of the present invention and a photograph (B) showing its bending characteristics.
  • FIG. 5 is a photograph of the microneedle patch of the present invention (A: before use, B: after use).
  • Figure 6 is a photograph of the specimen of the present invention microneedle provided in the antimicrobial test.
  • FIG. 7 to 9 are antimicrobial to antifungal test result photographs
  • FIG. 7 is a test result for Propionibacterium acnes ATCC 6919
  • FIG. 8 is a test result for Staphylococcus epidermidis ATCC 12228
  • FIG. 9 is a test for Trichophyton rubrum ATCC 28188. The result is.
  • 10-11 are schematic diagrams illustrating various shapes of the microneedle patch of the present invention.
  • FIG. 12 is a photograph showing the results of sensory evaluation by applying the microneedle patch of the present invention, showing the skin condition (right side) before attachment (left), attachment state (center), and 8 hours after attachment.
  • Figure 13 is a photograph showing an example attached to the test subject in the clinical trial applying the microneedle patch of the present invention.
  • FIG. 14 is an image showing a test site divided into six sections of a face area in an evaluation through a global acne grading system (GAGS) in a clinical trial.
  • GGS global acne grading system
  • FIG. 15 is a table showing intrinsic factors and global scores of each section shown in FIG. 14 in the evaluation through the acne severity system (GAGS) in clinical trials.
  • GGS acne severity system
  • FIG. 16 is a table of classification and status of adverse reactions in skin irritation evaluation in clinical trials.
  • 17 is a photograph showing the results of the photographing with the progress of the test period by attaching a magnesium microneedle patch to a test subject in a clinical trial.
  • Acne is a chronic inflammatory disease of the sebaceous gland of the hair sebaceous gland, and various skin changes such as cotton (Comedone, hardened sebum in hair follicles), papules (rising skin lesions less than 1 cm in size), pus blisters, nodules, and false cysts This may result in concave scars or enlarged scars. It occurs in the face, neck, chest, etc. where sebaceous glands are gathered, and inflammation of the sebaceous glands attached to hair follicles that make hair.
  • the exact cause of acne is not known, but several causes work in combination, rather than one cause.
  • the excess of male hormone during puberty stimulates the secretion of sebaceous glands, and the epithelium of hair follicles is dyskerosis (incomplete and immature keratinization).
  • Abnormal keratinization can cause hair follicles to be blocked, forming the scleroderma, the primary lesion of acne.
  • acne rash is known to be caused by propionibacterium acnes among the bacteria that reside in the hair follicles.
  • This acne-causing bacterium is the main cause of trouble when eating and growing sebum.In normal people, even if the bacteria are present on the skin, they do not cause any problems.However, since the hair follicles become clogged and sebum accumulates in the hair follicles, it grows quickly.
  • the acne-causing bacteria also eat fat (triglycerides) and then excrete butter-like substances, or fatty acids. This chemical change causes healthy weak acidic skin to alkalinize as the pH balance of oil breaks down, which in turn degrades the skin's own function and causes a vicious cycle of the skin.
  • a treatment method of a commonly used medicine or a medicine has been proposed.
  • the present invention was obtained as a result of continuous research on the microneedle developed as described above, and it was found that the biodegradable metal expresses antimicrobial activity against Propionibacterium acnes , an acne causing bacterium. By doing so, new applications of such biodegradable metals have been devised.
  • a substrate related to a biocompatible metal a substrate related to a method of manufacturing the same in the form of a microneedle, and a related substrate related to a series of metallic reactions occurring in the skin are according to the contents described in Korean Patent Application Publication No. 2017-0115449.
  • a substrate related to a biocompatible metal a substrate related to a method of manufacturing the same in the form of a microneedle, and a related substrate related to a series of metallic reactions occurring in the skin are according to the contents described in Korean Patent Application Publication No. 2017-0115449.
  • the biodegradable metal is not limited to the microneedles proposed as drug carriers, but it is clarified that the biodegradable metal acts alone as a functional composition having antibacterial activity against acne causing bacteria.
  • a biodegradable metal made of magnesium or zinc alone and a biodegradable metal mixed with other metals such as calcium in the form of a thin plate or a microneedle are prepared and their antibacterial activity against acne-causing bacteria was evaluated.
  • the biodegradable metal prepared by using magnesium, calcium, or zinc as a single material, or an alloy in which the metal is mixed in a specific range has its own antimicrobial activity without additional drug encapsulation.
  • the present invention provides a patch for acne alleviation and prevention, which is, in one aspect, a biodegradable metal represented by Formula 1 and having an antiacne bactericidal effect.
  • X is the one or more selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P.
  • the biodegradable metal according to the present invention is a metal having the property of being attached or inserted into the subcutaneous or epithelium, and absorbed and decomposed to release metal ions and decomposition products in the body, and includes magnesium (Mg), calcium (Ca), and zinc ( Zn) and the like is an alkaline earth-based biodegradable metal, and has a mechanism for releasing hydrogen gas by reacting with water, as shown in Schemes 1 to 3 below.
  • the biodegradable metal may be preferably made of magnesium (Mg), zinc (Zn), or the like as a single material, and particularly in terms of excellent biocompatibility and no toxicity in normal cells or tissues. Most preferably, it may be a biodegradable metal that is magnesium alone.
  • magnesium single material or zinc single material means pure magnesium or zinc with a purity of 95% or more, in addition to including unavoidable impurities generated during metal production.
  • biodegradable metals can be made from two or more metals as a material in order to accelerate the rate of degradation in the subcutaneous or epithelium, ie to produce a galvanic circuit.
  • the biodegradable metal may be coated with another type of second metal on the surface of the biodegradable metal represented by Formula 1 to produce a galvanic circuit.
  • the second metal may include sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold, manganese, calcium, and the like. It is not limited. In this case, in the case of containing the iron (Fe), in particular, it should not contain cron or nickel.
  • the biodegradable metal may be included in the form of a thin plate or a microneedle.
  • the microneedle may be a conventional soluble microneedle in the industry such as laser cutting, sheet metal processing, casting method, and etching method. It can be prepared by a method for producing, the manufacturing method is not particularly limited. For example, after manufacturing the thin sheet 10 made of a biodegradable metal as shown in Figure 1 and then molded in a certain shape using a laser cutting machine (marking machine), the microneedle can be manufactured by bending in a jig press.
  • a patch containing such a biodegradable metal can be used for the purpose of acne relief and prevention by itself, without a separate drug coating or supporting.
  • FIG. 2 is a schematic diagram of the microneedles 11 bent to process the microneedles into the skin.
  • the microneedle according to the present invention may be formed in one piece or may be composed of the microneedle 20 and the microneedle holder 21 as shown in FIG. 3.
  • the microneedle utilizing the form of the microneedle holder 21 may be twisted after the needle is inserted to artificially allow the needle to remain subcutaneously.
  • Figure 4 is a prototype photograph (A) of the microneedle manufactured according to an embodiment of the present invention and a photograph (B) showing its bending characteristics.
  • such a microneedle can be manufactured in a patch form in terms of facilitating application to the skin.
  • the microneedle patch is for fixing the microneedle to the skin, and is composed of a microneedle and a patch portion formed on an opposite side of the microneedle.
  • the size, shape and material of the patch can be used without particular limitation.
  • the microneedles used may be ionized and discolored subcutaneously.
  • the patch containing the biodegradable metal of the present invention When the patch containing the biodegradable metal of the present invention is applied to the skin, it exhibits an anti-acne effect by itself without the inclusion or application of other drugs, but in the sense of doubling the effect or shortening the time of effect expression, It may be desirable to involve a hydration step or skin soothing step prior to applying the patch of the invention.
  • the moisture supply step may be performed through the application of various moisturizing cosmetics, for example, toner or moisture supply mist
  • the skin soothing step is to apply a functional cosmetics or medicines known to calm skin redness or acne
  • the method may be performed by, but is not limited to.
  • This water supply step or skin soothing step simply serves to assist the anti-acne effect of the patch containing the biodegradable metal of the present invention, and the effect of the patch of the present invention is not realized only when the step is preceded. .
  • the present invention has been developed a new use of the biodegradable metal applied in the form of microneedles for acne alleviation and prevention, the use is present in the skin using the above-described biodegradable metal as a specimen through the embodiments described below
  • the purpose of this study is to evaluate the activity of various bacteria, and to identify that it is only active against acne-causing bacteria.
  • the sample provided is a sheet made of pure Mg (magnesium of 95% or more purity) containing inevitable impurities generated during manufacture (thickness of 100 ⁇ m), and cut to a predetermined standard as shown in FIG. Used as
  • P. acnes were inoculated in Reinforced clostridial medium (RCM) broth and incubated at 35 ⁇ 1 ° C for 3 days.
  • the cultured bacterial solution was inoculated in fresh RCM broth and incubated under the same conditions as above, and this process was repeated one more time. All cultures of the strain were maintained in anaerobic conditions using sterile liquid paraffin. Then used as test bacteria.
  • S. epidermidis was inoculated into Brain heart infusion broth and cultured at (35 ⁇ 1) ° C for 18 to 24 hours before being used as test bacteria.
  • T. rubrum was inoculated in Sabouraud dextrose agar (25 ⁇ 1) and incubated for 14 days at °C. 0.05% polysorbate 80 solution was dispensed on the solid medium in which the test bacteria were grown, and spores were removed using a spreader, followed by gauze to remove mycelia. Spore solution prepared in this way was adjusted to (1 ⁇ 9) ⁇ 10 7 CFU / mL was used as the test bacteria.
  • Each fungal culture was evenly inoculated with a sterile swab on a prepared Reinforced clostridial medium (RCM) agar, Tryptic soy agar, and Sabouraud dextrose agar, and a prepared sample (20 mm ⁇ 20 mm) was placed in the center of the medium.
  • RCM Reinforced clostridial medium
  • S. epidermidis at (35 ⁇ 1) °C (24 ⁇ 2) hours
  • T. rubrum 25 ⁇ 1) °C Incubated for 7 days. Thereafter, the test was carried out by measuring the zone of inhibition around the sample.
  • the width (W) of the growth stop was calculated according to the following Equation 1.
  • T total diameter of sample and low zone (mm)
  • the total diameter (T) of the sample and the low zone was 32 mm
  • the diameter (D) of the sample was observed to 20mm. Therefore, according to the above formula, the width W of the low zone was confirmed to be 6.0 mm (see FIG. 7).
  • the total diameter (T) of the sample and lowland was 20 mm and the diameter (D) of the sample was 20 mm. Therefore, according to the above formula, the width W of the low land was confirmed to be 0.0 mm (see FIG. 8).
  • the total diameter (T) of the sample and lowland was 20 mm and the diameter (D) of the sample was 20 mm. Therefore, according to the above formula, the width W of the low zone was confirmed to be 0.0 mm (see Fig. 9).
  • the biodegradable metal of the present invention has antimicrobial activity only against acne causing bacteria, the rest of the antibacterial to antifungal effect was not observed.
  • a microneedle was manufactured using a laser marker (JTY FIBER MA20, JT Y System). At this time, the tip angles of the microneedles were 15 °, 30 °, and 35 °, and the needle heights were 0.5 mm, 1.0 mm, and 1.5 mm.
  • the microneedle patch was prepared by attaching a hydrocolloid patch coated with an adhesive to the opposite side where the needle of the microneedle was produced.
  • the prepared microneedle patch was packaged and sterilized.
  • microneedle patch may be manufactured in various shapes in terms of acne relief and prevention, and examples thereof may include shapes such as those illustrated in FIGS. 10 to 11.
  • the microneedle patch obtained was 7 male 15-year-old students with acne skin, and the patch was applied to one of the acne areas of the face after cleansing.
  • the evaluation criteria are 5 points for the acne treatment effect is significant, that is, the acne skin area is clearly reduced and the acne inflammation is clearly reduced. Rather, acne was worsened and evaluated as one point, and then a comprehensive judgment was made as a total score, and the results are shown in Table 2 below.
  • Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Total score Invention microneedle patch 5 5 5 4 4 5 4 32
  • Figure 12 is a photograph showing the skin condition (left), the state of attachment (center), and the skin state (right) after 8 hours after attachment of the microneedle patch of a subject having forehead acne, from which the micro of the present invention Immediately after applying the needle patch, you'll see an immediate acne relief.
  • the test product was used once a day at the test site according to the prescribed method of use, and the effect was evaluated through visual evaluation.
  • the test site was carried out on the face area of the test subject.
  • the prescribed method of use is as follows.
  • FIG. 13 An example of applying a magnesium patch to a tester is shown in FIG. 13.
  • test subjects met the selection criteria, and 20 persons were selected and tested without the exclusion criteria.
  • test subjects suitable for the study After selecting the test subjects suitable for the study according to the selection and exclusion criteria, confirming the skin condition of the test subjects, and performing visual evaluation and photographing (VISIA-CR) before using the product (0 days) and 1 day of using the product, respectively. Then, 3 days after product use, 4 days after product use, and 5 days after product use.
  • VIPSIA-CR visual evaluation and photographing
  • test subjects were allowed to settle for 30 minutes in the waiting room under constant temperature and humidity (22 ⁇ 2 °C, RH40 ⁇ 60%) to adapt the skin surface temperature and humidity to the environment of the measurement space.
  • constant temperature and humidity 22 ⁇ 2 °C, RH40 ⁇ 60%
  • the device was evaluated by one investigator and the same area was measured by each researcher.
  • Photographs were taken with full face photographs using facial cameras (VISIA-CR, Canfield, USA) equipped with cameras (Canon, EOS6D, JAPAN), and the standard 2 measurement mode was used. Facial cameras (VISIA-CR, Canfield) fix the forehead and the chin to minimize the subject's movement, and the gray card is photographed together to see the change of light when shooting. Measurements were made before product use (day 0), after product use 1 day, after product use 3 days, and after product use 5 days. The overlay function was used to capture the same area, and only images were used in this study.
  • GAGS Global Acne Grading System
  • each subject was surveyed for the general evaluation (feeling) of the test product, evaluation of change after use, satisfaction with the product, and adverse reactions.
  • the evaluation of the questionnaire by the test subjects answered the questionnaire directly in five stages (5), satisfaction (4), moderate (3), dissatisfaction (2), and very dissatisfaction (1) for the measured items after using the test product. To do so.
  • the investigator determined the efficacy of the test product by obtaining a percentage of the number of subjects for each response.
  • the subjects were asked to answer the questionnaire about the test product and the feeling of use after use.
  • the evaluation items were evaluated in five stages: general satisfaction (feeling of use) and satisfaction with the product.
  • the visual evaluation result was conducted by comparing the difference before and after using the product, and the evaluation method was evaluated using the method described in item 3) of the above (2).
  • the paired t-test method was used for changes before and after the use of the product, and the statistical results were statistically significant when the significant difference of 5% (p ⁇ 0.05) used in the biological statistical analysis. Considered.
  • the survey results and product preferences were also evaluated based on the survey results.
  • the subjects who participated in this study were selected from 20 healthy adult male and female subjects with an average age of 21.9 ⁇ 2.9.
  • the 20 subjects completed the final test without dropping out.
  • test product showed statistically significant difference after 1 day of test product use, 3 days after product use, and 5 days after product use compared to before product use (day 0).
  • the skin irritation evaluation (self-evaluation) results of the test subjects are shown in Table 6 below.
  • the selective anti-acne bactericidal activity of the patch containing the non-toxic biodegradable metal having excellent biocompatibility is mainly due to the increase of the local pH due to OH - ions generated during the decomposition of the metals shown in Schemes 1 to 3. It is expected that, if the pure magnesium or pure zinc metal containing the components according to the formula (1) to accelerate the decomposition rate, a faster antibacterial effect is expected.
  • the patch to which the biodegradable metal of the present invention is applied is useful for alleviating and preventing acne by having antimicrobial activity against acne causing bacteria on its own without carrying a separate drug, and by using a simple method of applying it to the skin by manufacturing it in various forms It may be useful as a patch to prevent acne or to alleviate the caused acne.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a patch for alleviation and prevention of acne in which anti-acne bacteria activity is identified for a biodegradable metal represented by MgaZnbXc (wherein, a, b, and c are the weight percent of each component, a + b + c = 100 weight percent, a or b is the largest among 0 ≤ a ≤ 100, 0 ≤ b ≤ 100, and 0 ≤ c ≤ 10, and X is at least one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P), and a new use as a patch for alleviation and prevention of acne is proposed.

Description

여드름 완화 및 예방용 패치Acne Relief and Prevention Patch
본 발명은 여드름 완화 및 예방용 패치에 관한 것으로, 더욱 상세하게는 마그네슘을 주성분으로 포함하는 생체분해성 금속의 새로운 용도에 관한 발명이다. The present invention relates to a patch for alleviating and preventing acne, and more particularly, to a new use of a biodegradable metal containing magnesium as a main component.
마이크로 니들은 1998년 미국 조지아공대 프라우스니츠 그룹에서 반도체 공정기술을 이용하여 실리콘소자로 마이크로 니들 어레이를 만들어 약물전달에의 응용 가능성을 제시한 것을 시초로 많은 연구들이 활발하게 진행되고 있다. 마이크로 니들은 피부에 삽입할 때, 마이크로 니들이 구부러지거나 부러짐 없이 삽입될 수 있도록 충분히 높은 물리적 강도를 유지해야하므로 그에 적합한 강도와 형상 제어가 가능한 특성이 요구된다. 이러한 특성을 만족시키기 위하여 마이크로 니들의 소재로 스테인레스 스틸(stainless steel)이 사용되었으나 작은 particle이 몸에 남을 경우 염증(inflammation)이 발생하는 문제가 있었고, 폴리머(PLA, PGA, 생분해성 Copolymer)의 경우 침습(penetration)이 되지 않는 문제점이 있었다.Many researches have been actively conducted since the microneedles were proposed in 1998 by the Frausnits Group of Georgia Institute of Technology to make microneedle arrays of silicon devices using semiconductor process technology. When the microneedles are inserted into the skin, the microneedles must maintain a sufficiently high physical strength so that the microneedles can be inserted without being bent or broken. In order to satisfy these characteristics, stainless steel was used as the material of the microneedle, but inflammation occurred when small particles remained in the body, and polymers (PLA, PGA, and biodegradable copolymer) were used. There was a problem of not being penetration.
한국공개특허 제2016-0058261호는 폴리글리코라이드(PGA), 폴리락타이드-글리코라이드공중합체(PLGA), 히아룰론산(hyaluronic acid), 알긴산(alginic acid), 펙틴 등을 소재로 한 수용성 마이크로니들 및 이의 제조방법을 개시하였고, 한국등록특허 제1622388호는 실리콘 마이크로 니들 스탬프 및 그 제조방법을 개시하였고, 한국공개특허 제2015-0121053호는 실리콘, 이산화규소, 세라믹, 금속(스테인리스, 티탄, 니켈, 몰리브덴, 크롬, 코발트 등) 및 합성 또는 천연의 수지를 소재로하여 일본 뇌염 백신 항원을 코팅시킨 마이크로 니들을 개시하였다.Korean Unexamined Patent Publication No. 2016-0058261 is a water-soluble microorganism based on polyglycolide (PGA), polylactide-glycolide copolymer (PLGA), hyaluronic acid, alginic acid, pectin and the like. A needle and a manufacturing method thereof are disclosed, and Korean Patent No. 1622388 discloses a silicon micro needle stamp and a manufacturing method thereof, and Korean Patent Publication No. 2015-0121053 discloses a silicon, silicon dioxide, ceramic, metal (stainless steel, titanium, Nickel, molybdenum, chromium, cobalt and the like) and synthetic or natural resins have been disclosed for microneedle coated with Japanese encephalitis vaccine antigen.
상기와 같이, 지금까지의 마이크로 니들은 경구 투여를 통한 약물 전달 방식이나 주사를 통한 약물 전달 방식을 대체할 수 있는 대안적 약물 투여수단으로, 피부에 분포한 통각 신경을 자극하지 않고 표피를 투과하여 약물을 전달할 수 있는 기기, 즉 일종의 약물 전달체로서 사용되어 왔다. As described above, the microneedle up to now is an alternative drug administration means that can replace the drug delivery method through oral administration or injection method, and penetrates the epidermis without stimulating pain sensory nerves distributed in the skin. It has been used as a device capable of delivering drugs, a kind of drug carrier.
한편, 본 출원인에 의해 기 출원되어 공개된 한국공개특허 제2017-0115449호에는 생체분해성 금속을 이용한 마이크로니들 및 이를 포함하는 패치가 개시되어 있는데, 여기서는 약물전달체로서의 유용성과 함께 이것이 미네랄로 작용하여 자체적으로 주름개선에도 효과를 발현함을 확인한 바 있다. Meanwhile, Korean Patent Application Publication No. 2017-0115449, previously filed by the present applicant, discloses a microneedle using a biodegradable metal and a patch including the same. It has been confirmed that the effect is also expressed in wrinkle improvement.
본 발명은 종래 약물 전달 수단으로 개발되었던 마이크로 니들의 주성분인 생체분해성 금속의 새로운 용도를 제공하고자 한다. The present invention seeks to provide a novel use of biodegradable metals, which are the main component of microneedles that have been developed as conventional drug delivery means.
본 발명은 특히 별도의 약물을 포함하지 않으면서도, 마이크로 니들의 주성분으로 사용되던 생체분해성 금속 자체가 여드름 원인균에 대한 항균활성을 발현함을 확인하여, 특정의 생체분해성 금속의 여드름 완화 및 예방용으로서의 새로운 용도를 제공하고자 한다. The present invention is confirmed that the biodegradable metal itself, which was used as a main component of the microneedle, expresses antimicrobial activity against acne causing bacteria, and does not include a separate drug. We want to provide a new use.
본 발명은 화학식 1로 표시되는 생체분해성 금속이며, 항여드름균 효과를 가지는, 여드름 완화 및 예방용 패치를 제공한다.The present invention is a biodegradable metal represented by the formula (1), and has an anti acne bacterium effect, provides a patch for acne relief and prevention.
[화학식 1][Formula 1]
Mg aZn bX c Mg a Zn b X c
화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, 0≤a≤100, 0≤b≤100, 0≤c≤10 범위중 a 또는 b가 가장 크며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상임. In Formula 1, a, b, and c are weight percents of each component, and a + b + c = 100 wt%, where a or b is in a range of 0 ≦ a ≦ 100, 0 ≦ b ≦ 100, and 0 ≦ c ≦ 10. X is the one or more selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P.
이러한 여드름 완화 및 예방용 패치에 있어서, 생체분해성 금속은 마이크로 니들 형태로 포함되거나 박판 형태로 포함될 수 있다. In such acne relief and prevention patches, the biodegradable metal may be included in the form of microneedles or in the form of a thin plate.
본 발명의 바람직한 일 구현예에 의한 여드름 완화 및 예방용 패치에 있어서, 생체분해성 금속은 상기 화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, i) 90≤a≤100, 0≤b≤10, 0≤c≤10 또는 ii) 0≤a≤10, 90≤b≤100, 0≤c≤10이며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상인 것일 수 있다.In the patch for acne relief and prevention according to an embodiment of the present invention, the biodegradable metal is a, b and c in the formula (1) as the weight percent of each component, a + b + c = 100 weight percent, i) 90≤a≤100, 0≤b≤10, 0≤c≤10 or ii) 0≤a≤10, 90≤b≤100, 0≤c≤10, and X is Ca, Fe, Mn, Si , Na, Zr, Ce and P may be one or more selected from the group consisting of.
가장 바람직한 일 구현예에 의한 여드름 완화 및 예방용 패치에 있어서, 상기 생체분해성 금속은 불가피한 불순물을 포함한 순수 순도 95% 이상의 Mg일 수 있다. In the patch for preventing and preventing acne according to the most preferred embodiment, the biodegradable metal may be Mg of 95% or more pure purity including inevitable impurities.
본 발명의 일 구현예에 의한 여드름 완화 및 예방용 패치에 있어서, 생체분해성 금속은 2 이상의 금속 상(phase)이 갈바닉 회로를 생성하여 분해속도가 가속화되는 것일 수 있다. 이러한 생체분해성 금속은 Mg 2Ca 상을 포함하는 것, MgZn 상을 포함하는 것, 또는 Ca 2Mg 6Zn 3 상을 포함하는 것일 수 있다. In the patch for acne alleviation and prevention according to an embodiment of the present invention, the biodegradable metal may be one or more metal phases to generate a galvanic circuit to accelerate the decomposition rate. Such biodegradable metal may be one comprising an Mg 2 Ca phase, one comprising an MgZn phase, or one comprising a Ca 2 Mg 6 Zn 3 phase.
본 발명의 일 구현예에 의한 여드름 완화 및 예방용 패치에 있어서, 생체분해성 금속은 갈바닉 회로를 형성시키기 위하여 금속 표면에 다른 종류의 제2의 금속이 코팅된 것일 수 있다. 이때, 상기 제2의 금속은 나트륨, 마그네슘, 칼륨, 철, 니켈, 아연, 갈륨, 셀레늄, 스트론튬, 지르코늄, 몰리브덴, 니오븀, 탄탈륨, 타이타늄, 규소, 은, 금, 망간 및 칼슘으로 구성된 군에서 선택되는 1종 이상의 금속일 수 있다. In the patch for acne alleviation and prevention according to an embodiment of the present invention, the biodegradable metal may be coated with a second kind of second metal on the metal surface to form a galvanic circuit. At this time, the second metal is selected from the group consisting of sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold, manganese and calcium It may be one or more metals.
본 발명의 다른 일 구현예에서는 상술한 여드름 완화 및 예방용 패치를 여드름 피부에 부착하여 사용하는 방법을 제공한다.Another embodiment of the present invention provides a method for attaching and using the aforementioned acne relief and prevention patch on acne skin.
보다 바람직한 일 구현예에 의한 방법에 있어서, 여드름 완화 및 예방용 패치를 여드름 피부에 부착하기 전에 수분공급단계 또는 피부진정단계를 수행할 수 있다. In a method according to a more preferred embodiment, the water supply step or the skin soothing step may be performed before the acne relief and prevention patch is attached to the acne skin.
본 발명의 생체분해성 금속을 적용한 패치는 별도의 약물의 담지없이 자체적으로 여드름 원인균에 대한 항균 활성을 가져 여드름 완화 및 예방용으로 유용하며, 이를 다양한 형태로 제작하여 피부에 적용하는 간이한 방법을 통해 여드름을 예방하거나 유발된 여드름에 대한 완화 효과를 얻을 수 있다. The patch to which the biodegradable metal of the present invention is applied is useful for alleviating and preventing acne by having antimicrobial activity against acne causing bacteria on its own, without the need for a separate drug, and by using a simple method of applying it to the skin by making it in various forms. You can prevent acne or relieve the acne caused.
도 1은 생체분해성 금속으로 구성된 시트에 마이크로 니들을 가공한 마이크로 니들의 전개도이다.1 is an exploded view of microneedles in which microneedles are processed into sheets composed of biodegradable metals.
도 2는 가공된 마이크로 니들을 굽힘 가공한 마이크로 니들의 개략도이다.2 is a schematic view of a microneedle bent over the processed microneedles.
도 3은 팁 형태의 마이크로 니들과 마이크로 니들 홀더의 개략도이다.3 is a schematic view of a microneedle and microneedle holder in the form of a tip.
도 4는 본 발명의 마이크로 니들의 시제품 사진(A) 및 이의 굴곡 특성을 나타낸 사진(B)이다.4 is a prototype (A) of the microneedle of the present invention and a photograph (B) showing its bending characteristics.
도 5는 본 발명의 마이크로 니들 패치의 사진이다(A: 사용 전, B: 사용 후).5 is a photograph of the microneedle patch of the present invention (A: before use, B: after use).
도 6은 항균 시험에 제공한 본 발명 마이크로 니들의 시편 사진이다. Figure 6 is a photograph of the specimen of the present invention microneedle provided in the antimicrobial test.
도 7 내지 도 9는 항균 내지 항진균 시험결과 사진으로, 도 7은 Propionibacterium acnes ATCC 6919에 대한 시험결과이고, 도 8은 Staphylococcus epidermidis ATCC 12228에 대한 시험결과이며, 도 9는 Trichophyton rubrum ATCC 28188에 대한 시험결과이다. 7 to 9 are antimicrobial to antifungal test result photographs, FIG. 7 is a test result for Propionibacterium acnes ATCC 6919, FIG. 8 is a test result for Staphylococcus epidermidis ATCC 12228, and FIG. 9 is a test for Trichophyton rubrum ATCC 28188. The result is.
도 10 내지 도 11은 본 발명의 마이크로 니들 패치의 다양한 형상을 예시한 개략도이다. 10-11 are schematic diagrams illustrating various shapes of the microneedle patch of the present invention.
도 12는 본 발명의 마이크로 니들 패치를 적용하여 관능평가한 결과 사진으로, 부착전(좌측), 부착상태(가운데), 및 부착 후 8시간 경과시점의 피부상태(우측)를 나타낸다. 12 is a photograph showing the results of sensory evaluation by applying the microneedle patch of the present invention, showing the skin condition (right side) before attachment (left), attachment state (center), and 8 hours after attachment.
도 13은 본 발명의 마이크로 니들 패치를 적용한 임상실험에 있어서 시험 대상자에게 부착된 일예를 보여주는 사진이다.Figure 13 is a photograph showing an example attached to the test subject in the clinical trial applying the microneedle patch of the present invention.
도 14는 임상실험에 있어서 여드름 중증도 시스템(Global Acne Grading System: GAGS)을 통한 평가에서 얼굴 부위를 6개의 구간으로 나눈 시험 부위를 도시한 이미지이다. FIG. 14 is an image showing a test site divided into six sections of a face area in an evaluation through a global acne grading system (GAGS) in a clinical trial. FIG.
도 15는 임상실험에 있어서 여드름 중증도 시스템(Global Acne Grading System: GAGS)을 통한 평가에서 도 14로 도시한 각 구간의 고유 factor 및 global score를 나타낸 표이다. FIG. 15 is a table showing intrinsic factors and global scores of each section shown in FIG. 14 in the evaluation through the acne severity system (GAGS) in clinical trials.
도 16은 임상실험에 있어서 피부자극평가에서 이상반응 여부 및 등급을 분류한 표이다. FIG. 16 is a table of classification and status of adverse reactions in skin irritation evaluation in clinical trials.
도 17은 임상실험에 있어서 시험대상에 마그네슘 마이크로 니들 패치를 부착하여 시험 기간의 경과에 따른 사진촬영의 결과를 도시한 사진이다. 17 is a photograph showing the results of the photographing with the progress of the test period by attaching a magnesium microneedle patch to a test subject in a clinical trial.
여드름이란, 털 피지선 샘 단위의 만성 염증질환으로 면포(Comedone, 모낭 속에 고여 딱딱해진 피지), 구진(Papule, 1cm 미만 크기의 솟아 오른 피부 병변), 고름물집, 결절, 거짓낭 등 다양한 피부 변화가 나타나며, 이에 따른 후유증으로 오목한 흉터 또는 확대된 흉터를 남기기도 한다. 피지선이 모여 있는 얼굴, 목 가슴 등에 많이 발생하며 털을 만드는 모낭에 붙어있는 피지선에 염증이 생기는 질환을 말한다.Acne is a chronic inflammatory disease of the sebaceous gland of the hair sebaceous gland, and various skin changes such as cotton (Comedone, hardened sebum in hair follicles), papules (rising skin lesions less than 1 cm in size), pus blisters, nodules, and false cysts This may result in concave scars or enlarged scars. It occurs in the face, neck, chest, etc. where sebaceous glands are gathered, and inflammation of the sebaceous glands attached to hair follicles that make hair.
여드름의 정확한 원인은 밝혀지지 않고 있으나 한 가지 원인보다는 여러 원인이 복합적으로 작용하며, 그 한 원인으로 사춘기에 남성호르몬의 과잉으로 피지선의 분비가 왕성해지고 모낭의 상피가 이각화증(불완전하고 미숙한 각질화를 보이는 비정상적 각질화)을 일으켜 모낭이 막혀서 여드름의 기본 병변인 면포가 형성되는 것이 있다.The exact cause of acne is not known, but several causes work in combination, rather than one cause.The excess of male hormone during puberty stimulates the secretion of sebaceous glands, and the epithelium of hair follicles is dyskerosis (incomplete and immature keratinization). Abnormal keratinization) can cause hair follicles to be blocked, forming the scleroderma, the primary lesion of acne.
이 중 박테리아에 의한 여드름의 발진은 모낭 내에 상주하는 균 중 특히 프로피오니박테리움 아크네( Propionibacterium acnes)가 그 원인균으로 알려져 있다. 이 여드름 원인균은 피지를 먹고 자라면서 트러블 발생의 주된 원인이 되는데, 정상인에서는 이 균이 피부에 존재하더라도 전혀 문제를 일으키지 않으나, 모낭이 막혀 피지가 모낭 안에 쌓이게 되면서부터는 피지를 먹고 빠르게 자라난다. Among these bacteria, acne rash is known to be caused by propionibacterium acnes among the bacteria that reside in the hair follicles. This acne-causing bacterium is the main cause of trouble when eating and growing sebum.In normal people, even if the bacteria are present on the skin, they do not cause any problems.However, since the hair follicles become clogged and sebum accumulates in the hair follicles, it grows quickly.
또한 이 여드름 원인균은 지방(트리글리세라이드)을 먹은 뒤 버터와 비슷한 물질, 즉 지방산을 배설하게 된다. 이러한 화학적 변화는 건강한 약산성 피부가 유분의 pH 밸런스가 무너지면서 알칼리화되어 결국 피부 자체 기능이 저하되고 피부의 악순환을 초래한다. 이러한 프로피오니박테리움 아크네에 의해 유발되는 여드름을 예방 및 완화시키기 위하여 통상 바르는 약 또는 먹는 약의 치료방법이 제안되어 왔음은 물론이다.The acne-causing bacteria also eat fat (triglycerides) and then excrete butter-like substances, or fatty acids. This chemical change causes healthy weak acidic skin to alkalinize as the pH balance of oil breaks down, which in turn degrades the skin's own function and causes a vicious cycle of the skin. In order to prevent and alleviate the acne caused by Propionibacterium acne, it is a matter of course that a treatment method of a commonly used medicine or a medicine has been proposed.
한편, 본 출원인은 생체분해성 금속을 이용한 마이크로 니들을 개발한 바 있고 이에 대해 기 출원한 바 있다(한국공개특허 제2017-0115449호). On the other hand, the applicant has developed a microneedle using a biodegradable metal and has already applied for this (Korea Patent Publication No. 2017-0115449).
본 발명은 이와 같이 개발된 마이크로 니들에 대해 다각적인 연구를 지속적으로 수행한 결과로 얻어진 것으로, 해당 생체분해성 금속이 여드름 원인균인 프로피오니박테리움 아크네( Propionibacterium acnes)에 대해 항균활성을 발현함을 규명해냄으로써 이러한 생체분해성 금속의 새로운 용도를 안출해낸 것이다. The present invention was obtained as a result of continuous research on the microneedle developed as described above, and it was found that the biodegradable metal expresses antimicrobial activity against Propionibacterium acnes , an acne causing bacterium. By doing so, new applications of such biodegradable metals have been devised.
본 발명에서 생체적합성 금속과 관련한 기재, 이를 마이크로 니들 형태로 제조하는 방법에 관련한 기재, 그리고 피부에서 일어나는 일련의 금속적 반응에 대한 관련 기재는 한국공개특허 제2017-0115449호에 기재된 내용에 따름은 물론이다. In the present invention, a substrate related to a biocompatible metal, a substrate related to a method of manufacturing the same in the form of a microneedle, and a related substrate related to a series of metallic reactions occurring in the skin are according to the contents described in Korean Patent Application Publication No. 2017-0115449. Of course.
다만, 본 발명에서 생체분해성 금속은 약물 전달체로서 제안된 마이크로 니들로 제한되는 것이 아니라, 그것 자체가 여드름 원인균에 대한 항균활성을 갖는 기능적인 구성으로 단독적으로 작용하는 것임을 규명한다. However, in the present invention, the biodegradable metal is not limited to the microneedles proposed as drug carriers, but it is clarified that the biodegradable metal acts alone as a functional composition having antibacterial activity against acne causing bacteria.
본 발명에서는 마그네슘 또는 아연을 단독 소재로 한 생체분해성 금속과 상기 금속에 칼슘 등의 다른 종류의 금속을 혼합한 생체분해성 금속을 박판 형태 또는 마이크로 니들 형태로 제조하고, 이들의 여드름 원인균에 대한 항균활성을 평가하였다. 그 결과 마그네슘, 칼슘 또는 아연을 단독 소재로 하여 제조된 생체분해성 금속 또는 상기 금속에 다른 종류의 금속이 특정범위로 혼합된 합금은 별도의 약물 봉입없이도 그 자체가 항균활성을 가짐을 확인할 수 있었다.In the present invention, a biodegradable metal made of magnesium or zinc alone and a biodegradable metal mixed with other metals such as calcium in the form of a thin plate or a microneedle are prepared and their antibacterial activity against acne-causing bacteria Was evaluated. As a result, it was confirmed that the biodegradable metal prepared by using magnesium, calcium, or zinc as a single material, or an alloy in which the metal is mixed in a specific range, has its own antimicrobial activity without additional drug encapsulation.
따라서, 본 발명은 일 관점에서, 화학식 1로 표시되는 생체분해성 금속이며, 항여드름균 효과를 가지는, 여드름 완화 및 예방용 패치를 제공한다. Accordingly, the present invention provides a patch for acne alleviation and prevention, which is, in one aspect, a biodegradable metal represented by Formula 1 and having an antiacne bactericidal effect.
[화학식 1][Formula 1]
Mg aZn bX c Mg a Zn b X c
화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, 0≤a≤100, 0≤b≤100, 0≤c≤10 범위중 a 또는 b가 가장 크며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상임.In Formula 1, a, b, and c are weight percents of each component, and a + b + c = 100 wt%, where a or b is in a range of 0 ≦ a ≦ 100, 0 ≦ b ≦ 100, and 0 ≦ c ≦ 10. X is the one or more selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P.
상기 생체분해성 금속은 마그네슘 또는 아연을 가장 많이 포함하는 것이 바람직하다. 따라서, 상기 화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, i) 90≤a≤100, 0≤b≤10, 0≤c≤10 또는 ii) 0≤a≤10, 90≤b≤100, 0≤c≤10이며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상인 것이 바람직할 수 있다. The biodegradable metal preferably contains the most magnesium or zinc. Accordingly, in Formula 1, a, b and c are weight percent of each component, and a + b + c = 100 wt%, i) 90 ≦ a ≦ 100, 0 ≦ b ≦ 10, 0 ≦ c ≦ 10 or ii) 0≤a≤10, 90≤b≤100, 0≤c≤10, and X is preferably at least one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P. Can be.
본 발명에 따른 생체분해성 금속은 피하 또는 상피에 부착 또는 삽입된 후, 흡수 및 분해되어 금속이온 및 분해산물을 체내에 방출하는 특성을 갖는 금속으로, 마그네슘(Mg), 칼슘(Ca), 아연(Zn) 등은 알카리토금속 계열의 생체분해성 금속으로서, 하기의 반응식 1 내지 3으로 나타낸 것과 같이, 물과 반응하여 수소가스를 방출하는 메커니즘을 갖는다. The biodegradable metal according to the present invention is a metal having the property of being attached or inserted into the subcutaneous or epithelium, and absorbed and decomposed to release metal ions and decomposition products in the body, and includes magnesium (Mg), calcium (Ca), and zinc ( Zn) and the like is an alkaline earth-based biodegradable metal, and has a mechanism for releasing hydrogen gas by reacting with water, as shown in Schemes 1 to 3 below.
[반응식 1] Scheme 1
Mg + 2H 2O → Mg(OH) 2 + H 2 (gas)Mg + 2H 2 O → Mg (OH) 2 + H 2 (gas)
[반응식 2] Scheme 2
Ca + 2H 2O → Ca(OH) 2 + H 2 (gas)Ca + 2H 2 O → Ca (OH) 2 + H 2 (gas)
[반응식 3] Scheme 3
Zn + 2H 2O → Zn(OH) 2 + H 2 (gas) Zn + 2H 2 O → Zn (OH) 2 + H 2 (gas)
본 발명에 있어서, 상기 생체분해성 금속은 마그네슘(Mg), 아연(Zn) 등을 단독 소재로 하여 제조되는 것이 바람직할 수 있고, 특히 생체적합성이 우수하고 정상세포나 조직에서 독성을 나타내지 않는 측면에서 가장 좋기로는 마그네슘 단독소재인 생체분해성 금속인 것일 수 있다. 여기서, 마그네슘 단독소재 또는 아연 단독소재라는 용어는 금속 생산 과정에서 발생되는 불가피한 불순물을 포함하는 것 이외에, 순도 95% 이상의 순수 마그네슘이나 아연을 의미한다. In the present invention, the biodegradable metal may be preferably made of magnesium (Mg), zinc (Zn), or the like as a single material, and particularly in terms of excellent biocompatibility and no toxicity in normal cells or tissues. Most preferably, it may be a biodegradable metal that is magnesium alone. Herein, the term magnesium single material or zinc single material means pure magnesium or zinc with a purity of 95% or more, in addition to including unavoidable impurities generated during metal production.
다른 한편으로, 생체분해성 금속은 피하 또는 상피에서의 분해속도를 가속화시키기 위하여, 즉 갈바닉 회로를 생성시키기 위하여 2 이상의 금속을 소재로 하여 제조될 수 있다. 본 발명에 있어서, 상기 생체분해성 금속은 갈바닉 회로를 생성하기 위하여 상기 화학식 1로 표시되는 생체분해성 금속 표면에 다른 종류의 제2의 금속이 코팅된 것일 수 있다. 이때 제2의 금속은 나트륨, 마그네슘, 칼륨, 철, 니켈, 아연, 갈륨, 셀레늄, 스트론튬, 지르코늄, 몰리브덴, 니오븀, 탄탈륨, 타이타늄, 규소, 은, 금, 망간, 칼슘 등을 예시할 수 있으나 이에 한정되는 것은 아니다. 이때, 상기 철(Fe)을 포함하는 경우 특히 크론이나 니켈이 포함되지 않아야 한다.On the other hand, biodegradable metals can be made from two or more metals as a material in order to accelerate the rate of degradation in the subcutaneous or epithelium, ie to produce a galvanic circuit. In the present invention, the biodegradable metal may be coated with another type of second metal on the surface of the biodegradable metal represented by Formula 1 to produce a galvanic circuit. In this case, the second metal may include sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold, manganese, calcium, and the like. It is not limited. In this case, in the case of containing the iron (Fe), in particular, it should not contain cron or nickel.
본 발명의 여드름 완화 및 예방용 패치에 있어서 생체분해성 금속은 박판 형태 또는 마이크로 니들 형태로 포함될 수 있는데, 일예로 마이크로 니들은 레이저 커팅, 판금 공정, 캐스팅 공법, 에칭 공법 등 업계의 통상적인 용해성 마이크로니들을 제조하는 방법으로 제조될 수 있으며, 제조방법은 특별히 제한되지 않는다. 예를 들어 도 1와 같이 생체분해성 금속으로 구성된 박판형 시트(10)를 제조한 후 레이저 커팅기(마킹기)를 이용하여 일정 형태로 성형 후, 지그 프레스로 벤딩함으로써 마이크로 니들을 제조할 수 있다.In the patch for acne alleviation and prevention of the present invention, the biodegradable metal may be included in the form of a thin plate or a microneedle. For example, the microneedle may be a conventional soluble microneedle in the industry such as laser cutting, sheet metal processing, casting method, and etching method. It can be prepared by a method for producing, the manufacturing method is not particularly limited. For example, after manufacturing the thin sheet 10 made of a biodegradable metal as shown in Figure 1 and then molded in a certain shape using a laser cutting machine (marking machine), the microneedle can be manufactured by bending in a jig press.
본 발명에서는 이러한 생체분해성 금속을 포함하는 패치는 별도의 약물 코팅이나 담지없이, 그 자체로 여드름 완화 및 예방용의 목적으로 사용할 수 있다. In the present invention, a patch containing such a biodegradable metal can be used for the purpose of acne relief and prevention by itself, without a separate drug coating or supporting.
도 2는 가공된 마이크로 니들을 피부 관통을 위해 굽힘 가공한 마이크로 니들(11)의 개략도이다.2 is a schematic diagram of the microneedles 11 bent to process the microneedles into the skin.
본 발명에 따른 마이크로 니들은 일체형으로 구성되거나 도 3과 같이 마이크로 니들(20)과 마이크로 니들 홀더(21)로 구성될 수 있다. 마이크로 니들 홀더(21)형태를 활용한 마이크로 니들은 니들이 삽입 된 후 비틀림을 가하여 인위적으로 니들이 피하에 잔존하도록 할 수도 있다.The microneedle according to the present invention may be formed in one piece or may be composed of the microneedle 20 and the microneedle holder 21 as shown in FIG. 3. The microneedle utilizing the form of the microneedle holder 21 may be twisted after the needle is inserted to artificially allow the needle to remain subcutaneously.
도 4는 본 발명의 일 실시예에 따라 제조된 마이크로 니들의 시제품 사진(A) 및 이의 굴곡 특성을 나타낸 사진(B)이다.Figure 4 is a prototype photograph (A) of the microneedle manufactured according to an embodiment of the present invention and a photograph (B) showing its bending characteristics.
본 발명에 따르면 이러한 마이크로 니들을 피부에 적용하기 용이하도록 하는 측면에서 패치형태로 제작할 수 있다. According to the present invention, such a microneedle can be manufactured in a patch form in terms of facilitating application to the skin.
도 5에 도시된 바와 같이, 상기 마이크로 니들 패치는 마이크로 니들을 피부에 고정시키기 위한 것으로서, 마이크로 니들 및 상기 마이크로 니들의 반대 면에 형성된 패치부로 구성되어 있다. 상기 패치부의 크기, 모양 및 소재는 특별한 제한없이 이용 가능하다. 도 5의 B에 도시된 바와 같이, 사용된 마이크로 니들은 피하에서 이온화되어 변색될 수 있다.As shown in FIG. 5, the microneedle patch is for fixing the microneedle to the skin, and is composed of a microneedle and a patch portion formed on an opposite side of the microneedle. The size, shape and material of the patch can be used without particular limitation. As shown in FIG. 5B, the microneedles used may be ionized and discolored subcutaneously.
본 발명의 생체분해성 금속을 포함하는 패치를 피부에 적용시에는, 다른 약물의 봉입이나 도포없이도 그 자체로 항여드름 효과를 발현하나, 그 효과를 배가시키거나 효과발현 시간을 단축시키는 의미에서, 본 발명의 패치를 부착하기 전에 수분공급단계나 피부진정단계를 수반하는 것이 바람직할 수 있다. 여기서, 수분공급단계는 다양한 보습용 화장품들, 일예로 토너 또는 수분 공급용 미스트 등의 도포를 통해서 수행될 수 있고, 피부진정단계는 피부 홍조 또는 여드름을 진정시키는 것으로 알려진 기능성 화장품이나 의약품을 도포하는 방법을 통해 수행될 수 있으나, 이에 한정되는 것은 아니다.When the patch containing the biodegradable metal of the present invention is applied to the skin, it exhibits an anti-acne effect by itself without the inclusion or application of other drugs, but in the sense of doubling the effect or shortening the time of effect expression, It may be desirable to involve a hydration step or skin soothing step prior to applying the patch of the invention. Here, the moisture supply step may be performed through the application of various moisturizing cosmetics, for example, toner or moisture supply mist, the skin soothing step is to apply a functional cosmetics or medicines known to calm skin redness or acne The method may be performed by, but is not limited to.
이러한 수분공급단계 또는 피부진정단계는 단순히 본 발명의 생체분해성 금속을 포함하는 패치의 항여드름 효과를 보조하는 역할을 할 뿐이며, 이러한 단계가 선행되어야만 본 발명 패치의 효과가 구현되는 것이 아님은 물론이다. This water supply step or skin soothing step simply serves to assist the anti-acne effect of the patch containing the biodegradable metal of the present invention, and the effect of the patch of the present invention is not realized only when the step is preceded. .
본 발명은 마이크로 니들의 형태로 적용된 생체분해성 금속의 여드름 완화 및 예방용으로서의 새로운 용도를 개발한 것으로, 이러한 용도는 이하에서 기재되는 실시예를 통해, 상술한 생체분해성 금속을 시편으로 하여 피부에 존재하는 다양한 균들에 대하여 그 활성을 평가하고, 그것이 택일적으로 여드름 원인균에 대해서만 활성을 나타냄을 규명하는 방법을 통해 확인하고자 한다. The present invention has been developed a new use of the biodegradable metal applied in the form of microneedles for acne alleviation and prevention, the use is present in the skin using the above-described biodegradable metal as a specimen through the embodiments described below The purpose of this study is to evaluate the activity of various bacteria, and to identify that it is only active against acne-causing bacteria.
이하, 본 발명을 실시예에 의거 상세히 설명하는바, 본 발명이 이들 실시예에 의해 한정되는 것이 아님은 물론이다. Hereinafter, the present invention will be described in detail with reference to Examples, of course, the present invention is not limited to these Examples.
<실시예 1><Example 1>
본 발명의 생체분해성 금속에 대한 항여드름균 활성을 평가하기 위하여 한국화학융합시험연구원에 시료를 제공하여 다음과 같은 방법으로 항균 및 항진균 시험을 수행하였다. In order to evaluate the anti-acne bacterium activity against the biodegradable metal of the present invention, a sample was provided to the Korea Institute of Chemical Convergence Testing and the antimicrobial and antifungal test was performed in the following manner.
이때 제공한 시료는 제조시 발생되는 불가피한 불순물을 포함한 순수 Mg(순도 95% 이상의 마그네슘)를 이용하여 시트를 제작(두께 100㎛)한 것으로, 도 6의 사진과 같이 소정 규격으로 절단하여 실험의 시료로써 사용되었다. At this time, the sample provided is a sheet made of pure Mg (magnesium of 95% or more purity) containing inevitable impurities generated during manufacture (thickness of 100 μm), and cut to a predetermined standard as shown in FIG. Used as
<시험 장치 및 재료><Test equipment and materials>
(1) 시험 장치(1) test device
Autoclave (코아텍, 대한민국)Autoclave (COATEC, South Korea)
Dry oven (Jisico, 대한민국)Dry oven (Jisico, south korea)
Water bath (Polyscience, USA)Water bath (Polyscience, USA)
Incubator (Memmert, Germany)Incubator (Memmert, Germany)
pH meter (Thermo Orion, USA)pH meter (Thermo Orion, USA)
Stop watch (Time Art, Japan)Stop watch (Time Art, Japan)
Vortex mixer (Thermolyne, USA)Vortex mixer (Thermolyne, USA)
Container (Iwaki Pyrex, Japan)Container (Iwaki Pyrex, Japan)
Sterile pipette (Falcon, USA)Sterile pipette (Falcon, USA)
Petri dish (SPL, 대한민국)Petri dish (SPL, South Korea)
Volumetric flask (Myung Sung, 대한민국)Volumetric flask (Myung Sung, South Korea)
Mechanical shaker (Jisico, 대한민국)Mechanical shaker (Jisico, south korea)
Clean bench (수공양행, 대한민국)Clean bench (Suyang, South Korea)
Colony counter (덕우과학, 대한민국)Colony counter (Dukwoo Science, South Korea)
Anaerobic container (DIFCO, USA)Anaerobic container (DIFCO, USA)
(2) 시험 재료(2) test material
1) 시험균주1) Test strain
한국미생물보존센터로부터 분양받음Received from Korea Microbial Conservation Center
- Propionibacterium acnes ATCC 6919 Propionibacterium acnes ATCC 6919
- Staphylococcus epidermidis ATCC 12228 Staphylococcus epidermidis ATCC 12228
- Trichophyton rubrum ATCC 28188 Trichophyton rubrum ATCC 28188
2) 배지 및 시약2) Medium and Reagent
- Reinforced clostridial medium broth (DIFCO, USA)Reinforced clostridial medium broth (DIFCO, USA)
- Brain heart infusion broth (DIFCO, USA)Brain heart infusion broth (DIFCO, USA)
- Sabouraud dextrose broth (DIFCO, USA)Sabouraud dextrose broth (DIFCO, USA)
- Reinforced clostridial medium agar (DIFCO, USA)Reinforced clostridial medium agar (DIFCO, USA)
- Tryptic soy agar (DIFCO, USA)Tryptic soy agar (DIFCO, USA)
- Sabouraud dextrose agar (DIFCO, USA)Sabouraud dextrose agar (DIFCO, USA)
- GaspakTM EZ (DIFCO, USA)GaspakTM EZ (DIFCO, USA)
- 0.05 % polysorbate 80 solution0.05% polysorbate 80 solution
- 멸균액체파라핀-Sterile liquid paraffin
(3) 시험방법 (Test method)(3) Test method
1) 시험방법1) Test method
a. 시험균의 전배양 및 조제a. Preculture and Preparation of Test Bacteria
P. acnes는 Reinforced clostridial medium (RCM) broth에 접종하여 (35 ± 1) ℃에서 3일 동안 배양하였다. 배양된 균액을 새로운 RCM broth에 접종하고 상기와 동일한 조건으로 배양한 후, 이 과정을 1회 추가로 반복하였다. 균주의 모든 배양 과정에서 멸균 액체 파라핀을 이용하여 혐기적 조건을 유지시켜 주었다. 이 후 시험균액으로 사용하였다. P. acnes were inoculated in Reinforced clostridial medium (RCM) broth and incubated at 35 ± 1 ° C for 3 days. The cultured bacterial solution was inoculated in fresh RCM broth and incubated under the same conditions as above, and this process was repeated one more time. All cultures of the strain were maintained in anaerobic conditions using sterile liquid paraffin. Then used as test bacteria.
S. epidermidis는 Brain heart infusion broth에 접종하여 (35 ± 1) ℃에서 (18 ~ 24)시간 동안 배양 후 시험균액으로 사용하였다. S. epidermidis was inoculated into Brain heart infusion broth and cultured at (35 ± 1) ° C for 18 to 24 hours before being used as test bacteria.
T. rubrum는 Sabouraud dextrose agar에 접종하여 (25 ± 1) ℃에서 14일 동안 배양하였다. 시험균이 자란 고체 배지 위에 0.05 % polysorbate 80 solution을 분주하고 spreader를 이용하여 포자를 떼어낸 후 거즈를 통과시켜 균사를 제거하였다. 이런 방식으로 조제된 spore solution을 (1 ~ 9)ㅧ 10 7 CFU/mL가 되도록 조정하여 시험균액으로 사용하였다. T. rubrum was inoculated in Sabouraud dextrose agar (25 ± 1) and incubated for 14 days at ℃. 0.05% polysorbate 80 solution was dispensed on the solid medium in which the test bacteria were grown, and spores were removed using a spreader, followed by gauze to remove mycelia. Spore solution prepared in this way was adjusted to (1 ~ 9) ㅧ 10 7 CFU / mL was used as the test bacteria.
b. 시험 절차b. Test procedure
미리 준비된 Reinforced clostridial medium (RCM) agar, Tryptic soy agar 및 Sabouraud dextrose agar 위에 각각의 균 배양액을 멸균된 면봉으로 고르게 접종하고 배지 중앙에 준비된 시료(20mmㅧ20mm)를 올려놓았다. 이 후 P. acnes는 혐기 조건 (35 ± 1)℃ 에서 5일 동안 배양하였으며, S. epidermidis는 (35 ± 1) ℃ 에서 (24 ± 2)시간, T. rubrum는 (25 ± 1) ℃에서 7일 동안 배양하였다. 이 후, 시료 주위의 균 성장저지대 (Zone of inhibition)를 측정하는 방식으로 시험을 실시하였다.Each fungal culture was evenly inoculated with a sterile swab on a prepared Reinforced clostridial medium (RCM) agar, Tryptic soy agar, and Sabouraud dextrose agar, and a prepared sample (20 mm × 20 mm) was placed in the center of the medium. After that, P. acnes was incubated for 5 days at anaerobic condition (35 ± 1) ℃, S. epidermidis at (35 ± 1) ℃ (24 ± 2) hours, T. rubrum at (25 ± 1) ℃ Incubated for 7 days. Thereafter, the test was carried out by measuring the zone of inhibition around the sample.
2) 결과 판독2) read result
다음 식 1에 따라 성장저지대의 폭(W)을 계산하였다.The width (W) of the growth stop was calculated according to the following Equation 1.
<식 1><Equation 1>
W =  (T-D)/2       W =-(T-D) / 2
W : 저지대의 폭 (mm)W: width of lowland (mm)
T : 시료와 저지대의 전체지름 (mm)T: total diameter of sample and low zone (mm)
D : 시료의 지름 (mm) D: diameter of sample (mm)
시험균주Test strain TT DD WW
P. acnesP. acnes 3232 2020 6.06.0
S. epidermidis S. epidermidis 2020 2020 0.00.0
T. rubrum T. rubrum 2020 2020 0.00.0
상기 표 1로 요약한 것과 같이, P. acnes 에 대한 항균효과 결과, 시료와 저지대의 전체지름(T)은 32 mm, 시료의 지름(D)은 20mm로 관찰되었다. 따라서, 상기의 계산식에 따라 저지대의 폭(W)은 6.0 mm로 확인되었다(도 7 참조).As summarized in Table 1, as a result of the antimicrobial effect on P. acnes , the total diameter (T) of the sample and the low zone was 32 mm, the diameter (D) of the sample was observed to 20mm. Therefore, according to the above formula, the width W of the low zone was confirmed to be 6.0 mm (see FIG. 7).
S. epidermidis 에 대한 항균효과 결과, 시료와 저지대의 전체지름(T)은 20 mm, 시료의 지름(D)은 20 mm로 관찰되었다. 따라서 상기의 계산식에 따라 저지대의 폭 (W)은 0.0 mm로 확인되었다(도 8 참조). As a result of antimicrobial effect on S. epidermidis , the total diameter (T) of the sample and lowland was 20 mm and the diameter (D) of the sample was 20 mm. Therefore, according to the above formula, the width W of the low land was confirmed to be 0.0 mm (see FIG. 8).
T. rubrum 에 대한 항진균효과 결과, 시료와 저지대의 전체지름 (T)은 20 mm, 시료의 지름 (D)은 20 mm로 관찰되었다. 따라서 상기의 계산식에 따라 저지대의 폭 (W)은 0.0 mm로 확인되었다(도 9 참조). As a result of antifungal effect on T. rubrum , the total diameter (T) of the sample and lowland was 20 mm and the diameter (D) of the sample was 20 mm. Therefore, according to the above formula, the width W of the low zone was confirmed to be 0.0 mm (see Fig. 9).
본 시험 조건하에서 시료[Mg Micro Carrier Multi Care로 명명]에 대한 P. acnes, S. epidermidisT.rubrum의 저지대는 각각 6.0 mm, 0.0 mm 및 0.0 mm로 나타났다.Under this test condition, the lowlands of P. acnes , S. epidermidis and T.rubrum for the samples (named Mg Micro Carrier Multi Care) were 6.0 mm, 0.0 mm and 0.0 mm, respectively.
결과적으로, 본 발명의 생체분해성 금속은 여드름 원인균에 대해서만 항균 활성을 가지며, 나머지는 항균 내지 항진균효과가 관찰되지 않았다. As a result, the biodegradable metal of the present invention has antimicrobial activity only against acne causing bacteria, the rest of the antibacterial to antifungal effect was not observed.
<실시예 2> 마이크로 니들 및 패치의 제작Example 2 Fabrication of Micro Needle and Patch
상기 실시예 1의 항균활성 평가시 제공하였던 시트와 동일한 생체분해성 금속 시트를 제작한 후, 레이저 마킹기(JTY FIBER MA20, 제이티와이시스템)를 이용하여 마이크로 니들을 제작하였다. 이때, 마이크로 니들의 선단각은 15°, 30° 및 35°로 하였고, 니들 높이는 0.5㎜, 1.0㎜ 및 1.5㎜로 하였다. After producing the same biodegradable metal sheet as the sheet provided in the evaluation of the antimicrobial activity of Example 1, a microneedle was manufactured using a laser marker (JTY FIBER MA20, JT Y System). At this time, the tip angles of the microneedles were 15 °, 30 °, and 35 °, and the needle heights were 0.5 mm, 1.0 mm, and 1.5 mm.
마이크로 니들의 바늘이 생성된 반대쪽 면에 접착제가 도포된 하이드로 콜로이드 패치를 부착하여 마이크로 니들 패치를 제조하였다. 제조된 마이크로 니들 패치는 포장 및 멸균시켰다.The microneedle patch was prepared by attaching a hydrocolloid patch coated with an adhesive to the opposite side where the needle of the microneedle was produced. The prepared microneedle patch was packaged and sterilized.
이와 같은 마이크로 니들 패치는 여드름의 완화 및 예방을 위한 측면에서 다양한 형상으로 제작될 수 있는데, 일예로 도 10 내지 도 11로 도시한 것과 같은 형상들을 일예로 들 수 있다. Such a microneedle patch may be manufactured in various shapes in terms of acne relief and prevention, and examples thereof may include shapes such as those illustrated in FIGS. 10 to 11.
이와 같이 얻어진 마이크로 니들 패치에 대하여 여드름 피부를 가지고 있는 15세 남학생 7명으로 하여 세안 후 얼굴의 여드름 부위 중 한 곳에 패치를 부착하도록 한 후 여드름 완화효과를 7일 동안 관찰하였다. The microneedle patch obtained was 7 male 15-year-old students with acne skin, and the patch was applied to one of the acne areas of the face after cleansing.
평가 기준으로 여드름 치료효과가 현저한 경우, 즉, 여드름 피부 면적이 명백히 줄어들고 여드름 염증 정도도 명백히 줄어드는 경우 5점, 이러한 개선 정도가 중등인 경우 4점, 경등인 경우 3점, 불변인 경우 2점, 오히려 여드름이 악화된 경우 1점으로 하여 평가한 후 총점으로서 종합적인 판정을 하였으며, 그 결과를 하기 표 2에 나타내었다.The evaluation criteria are 5 points for the acne treatment effect is significant, that is, the acne skin area is clearly reduced and the acne inflammation is clearly reduced. Rather, acne was worsened and evaluated as one point, and then a comprehensive judgment was made as a total score, and the results are shown in Table 2 below.
피험자 1 Subject 1 피험자 2 Subject 2 피험자 3 Subject 3 피험자 4 Subject 4 피험자 5Subject 5 피험자 6Subject 6 피험자 7Subject 7 평가총점Total score
본 발명 마이크로니들 패치Invention microneedle patch 55 55 55 44 44 55 44 3232
상기 표 2로 알 수 있듯이 평가결과 대다수 피험자의 평가결과가 5점을 보여 실질적으로 여드름 완화에 큰 영향을 줌을 알 수 있다.As can be seen in Table 2 above, the evaluation results of the majority of the subjects showed five points, which can be seen to have a substantial effect on acne relief.
한편, 도 12는 이마 여드름을 갖는 피험자의 마이크로 니들 패치 부착전 피부상태(좌측), 부착상태(가운데) 및 부착후 8시간 경과후의 피부상태(우측)를 나타낸 사진으로, 이로부터 본 발명의 마이크로 니들 패치를 부착한 후 8시간 만에 즉각적인 여드름 완화 효과를 확인할 수 있다. On the other hand, Figure 12 is a photograph showing the skin condition (left), the state of attachment (center), and the skin state (right) after 8 hours after attachment of the microneedle patch of a subject having forehead acne, from which the micro of the present invention Immediately after applying the needle patch, you'll see an immediate acne relief.
<실시예 3> 임상실험Example 3 Clinical Trials
본 발명의 생체분해성 금속에 대한 여드름성 피부적합성을 평가하기 위하여 충청북도 화장품임상연구지원센터에 의뢰하여 다음과 같은 방법으로 임상평가를 수행하였다. In order to evaluate the acne skin compatibility of the biodegradable metal of the present invention was commissioned to the Chungcheongbuk-do Cosmetic Clinical Research Support Center was carried out clinical evaluation in the following way.
(1) 시험방법(1) Test method
만 18 내지 40세의 성인 남·여를 대상으로 수행하였다. 시험 부위에 1일 1회 시험 제품을 정해진 사용 방법에 따라 사용하도록 하였으며, 육안평가를 통하여 효과를 평가하였다. 평가는 센터 내부 지침서(SOP)에 준하여 수행하였으며, 식품의약품안전처 고시에 규정하지 않은 사항은 참고문헌을 참조하여 수행하였다. 시험 부위는 시험 대상자의 안면 부위에 실시하였다. The study was performed on male and female adults aged 18 to 40 years. The test product was used once a day at the test site according to the prescribed method of use, and the effect was evaluated through visual evaluation. The evaluation was carried out in accordance with the Center's Internal Guidelines (SOP), and matters not specified in the Ministry of Food and Drug Safety Notice were referred to the references. The test site was carried out on the face area of the test subject.
정해진 사용방법은 다음과 같다.The prescribed method of use is as follows.
① 깨끗이 세안한 후, 피부를 정돈한다. ① After cleansing, prepare the skin.
② 고농도 센텔라 앰플(수분공급 내지 진정효과)이 포함된 주사기의 마개를 분리한다. ② Remove the stopper of the syringe containing high concentration Centella ampoule (moisture supply or sedation effect).
③ 마그네슘 패치(순도 95% 이상의 마그네슘으로 제작)의 마이크로 캐리어에 고농도 센텔라 앰플을 적당량 떨어뜨린다. ③ Drop a high concentration of Centella ampoule on the microcarrier of magnesium patch (made of 95% or more of magnesium).
④ 마그네슘 패치에 손이 닿지 않도록 보호필름을 제거한다. ④ Remove the protective film from touching the magnesium patch.
⑤ 취침 전, 패치를 케어가 필요한 곳에 위치하도록 밀착한 후, 자극을 느낄 수 있도록 여러 번 눌러준다. ⑤ Before going to bed, close the patch to the place where care is needed and press it several times to feel the irritation.
⑥ 다음날 아침, 패치를 떼어낸다. ⑥ Remove the patch the next morning.
⑦ 패치를 떼어낸 자리에 하이드로콜로이드 밴드를 부착하여 주간에 유지하도록 한다. ⑦ Attach the hydrocolloid band to the spot where you removed the patch.
시험자에 마그네슘 패치를 적용한 일예는 도 13과 같다. An example of applying a magnesium patch to a tester is shown in FIG. 13.
시험 대상자는 선정기준에 적합하며, 제외기준이 적용되지 않는 자로 20명을 선정하여 시험하였다. The test subjects met the selection criteria, and 20 persons were selected and tested without the exclusion criteria.
시험 대상자 선정, 제외기준에 따라 연구에 적합한 시험 대상자를 선정하고, 시험 대상자의 피부 상태를 확인한 후, 육안평가 및 사진촬영(VISIA-CR)을 각각 제품사용 전(0일), 제품 사용 1일 후, 제품 사용 3일 후, 제품 사용 4일 후 및 제품 사용 5일 후에 실시하였다. After selecting the test subjects suitable for the study according to the selection and exclusion criteria, confirming the skin condition of the test subjects, and performing visual evaluation and photographing (VISIA-CR) before using the product (0 days) and 1 day of using the product, respectively. Then, 3 days after product use, 4 days after product use, and 5 days after product use.
(2) 측정 및 평가 방법(2) measuring and evaluation method
1) 준비 단계 1) Preparation Step
평가를 위하여 시험 대상자는 항온·항습(22±2℃, RH40~60%)조건의 대기실에서 30분 간 안정을 취하여 피부 표면 온도와 습도를 측정 공간의 환경에 적응하게 하였다. 객관적 측정을 위하여 기기 평가는 연구자 1인이 매 측정시 동일한 부위를 측정하였고, 육안평가는 연구자 2인이 평가하였다. For evaluation, the test subjects were allowed to settle for 30 minutes in the waiting room under constant temperature and humidity (22 ± 2 ℃, RH40 ~ 60%) to adapt the skin surface temperature and humidity to the environment of the measurement space. For the purpose of objective measurement, the device was evaluated by one investigator and the same area was measured by each researcher.
2) 사진 촬영 2) Take a picture
사진 촬영은 사진기(Canon, EOS6D, JAPAN)가 장착된 안면 촬영기(VISIA-CR, Canfield, USA)를 이용한 얼굴 전면 사진 촬영을 하였으며, 촬영은 Standard 2 측정 mode를 사용하였다. 안면촬영기(VISIA-CR, Canfield)는 시험 대상자의 움직임을 최소화하기 위해 이마와 턱을 고정하며, 촬영 시 빛의 변화를 알 수 있게 gray card가 함께 촬영된다. 측정은 제품 사용 전(0일), 제품 사용 1일 후, 제품 사용 3일 후, 제품 사용 5일 후에 시행하였고, 동일한 부위 촬영을 위해 overlay 기능을 사용하였으며, 본 연구에서는 이미지만 활용하였다. Photographs were taken with full face photographs using facial cameras (VISIA-CR, Canfield, USA) equipped with cameras (Canon, EOS6D, JAPAN), and the standard 2 measurement mode was used. Facial cameras (VISIA-CR, Canfield) fix the forehead and the chin to minimize the subject's movement, and the gray card is photographed together to see the change of light when shooting. Measurements were made before product use (day 0), after product use 1 day, after product use 3 days, and after product use 5 days. The overlay function was used to capture the same area, and only images were used in this study.
3) 육안평가 3) Visual evaluation
육안평가는 두 명의 전문가에 의해 이중맹검(Double-blind test)로 평가하였다. Visual evaluation was performed by two experts on a double-blind test.
두 전문가의 평가에 차이가 있을 경우에는 적합성성은 낮은 단계를, 피부 이상반응은 높은 단계를 선택하여 평가하였다. In the case of differences between the two experts, a low level of suitability and a high level of skin adverse reactions were evaluated.
육안평가는 여드름 중증도 시스템(Global Acne Grading System: GAGS)을 통하여 평가하였다. GAGS는 안면부위, 가슴 및 등 부위를 모피지선 단위(Pilosebaceous units)의 표면적 분포 및 밀도에 따라 6개의 구간으로 나누어 분석하였으며, 각 구간마다 고유의 factor를 부여한 후 병변 부위에 따라 점수(Local score)를 주어 Global score에 반영하고 등급을 정하여 평가하였다. 6개의 구간은 도 14로 도시한 것과 같다. Visual evaluation was performed using the Global Acne Grading System (GAGS). GAGS analyzed the facial, chest and back areas into six sections according to the surface area distribution and density of the pilosebaceous units, and assigned a unique factor to each section. Was given to the global score and evaluated by rating. The six sections are as shown in FIG.
또한, 각 구간의 고유 factor 및 global score는 도 15에 나타낸 내용과 같다. In addition, the unique factor and the global score of each section are as shown in FIG.
4) 설문 평가 4) Survey Evaluation
설문은 시험 대상자의 방문(제품 사용 5일 후)시 각각 시험 대상자를 대상으로 시험 제품의 일반적 평가(사용감), 사용 후 변화 평가, 제품에 대한 만족도, 이상반응 등을 설문 조사하였다. In the questionnaire, each subject was surveyed for the general evaluation (feeling) of the test product, evaluation of change after use, satisfaction with the product, and adverse reactions.
a. 유효성 평가 설문 조사(Global Assessment of Efficacy) a. Global Assessment of Efficacy
시험 대상자에 의한 설문 평가는 시험 제품 사용 후 측정 항목에 대하여 매우 만족(5), 만족(4), 보통(3), 불만족(2), 매우 불만족(1)의 5단계로 직접 설문조사에 답하도록 하였다. 연구자는 각 답변에 대한 시험 대상자 수의 백분율을 구하여 시험 제품의 효능 여부를 판단하였다. The evaluation of the questionnaire by the test subjects answered the questionnaire directly in five stages (5), satisfaction (4), moderate (3), dissatisfaction (2), and very dissatisfaction (1) for the measured items after using the test product. To do so. The investigator determined the efficacy of the test product by obtaining a percentage of the number of subjects for each response.
b. 제품 기호도 설문 조사 b. Product symbol road survey
시험 제품과 사용 후 제품 사용감에 대하여 시험 대상자가 직접 설문 조사에 답하도록 하였다. 평가 항목은 일반적 평가(사용감)와 제품에 대한 만족도에 대하여 매우 만족(5), 만족(4), 보통(3), 불만족(2), 매우 불만족(1)의 5단계로 평가하도록 하였다. The subjects were asked to answer the questionnaire about the test product and the feeling of use after use. The evaluation items were evaluated in five stages: general satisfaction (feeling of use) and satisfaction with the product.
5) 순응도 평가 5) Compliance assessment
제품 사용 시작일부터 종료된 시점까지 순응 일지에 제품 도포 여부 및 이상반응 여부를 작성하도록 하였다. From the start date of use of the product to the end of the use, the compliance log was written to indicate whether the product was applied or not.
6) 피부자극평가6) Skin irritation evaluation
시험 제품에 대해 이상반응인 홍반(Erythema), 부종(Edema), 인설(Scaling), 가려움(Itching), 자통(Stinging), 작열감(Burning), 뻣뻣함(Tightness), 따끔거림(Prickling)이나 다른 이상반응이 발생하는지의 존재 여부를 면밀히 관찰하고 피부 이상반응이 나타날 시 심한 정도에 따라 등급을 표시하고 이에 대한 검사 소견을 작성하였다. 방문하는 날이 아니더라도 시험에 더 이상 참가 할 수 없게 되는 경우는 본인의 서명이 첨부된 "시험참가 포기동의서"를 쓰도록 하였다. Erythema, Edema, Scaling, Itching, Stinging, Burning, Tightness, Prickling or other abnormalities of the test product The presence or absence of a reaction was closely monitored and graded according to the severity of skin adverse reactions, and test findings were prepared. If you are no longer able to participate in the test, even if it is not on the day you visited, you must write a "Sign-up Agreement" with your signature.
이상반응 여부 및 등급 분류표는 도 16과 같다. Adverse reaction status and classification table is shown in FIG.
(3) 결과분석(3) Result Analysis
1) 육안평가1) Visual evaluation
육안평가 결과는 제품 사용 전후 차이를 비교하여 진행되었으며, 평가 방법은 상기 (2)의 3) 항목에 기재된 방법을 이용하여 평가하였다. The visual evaluation result was conducted by comparing the difference before and after using the product, and the evaluation method was evaluated using the method described in item 3) of the above (2).
2) 통계 분석2) statistical analysis
평가 결과는 제품의 사용 전·후 변화에 대하여 쌍체검정(paired t -test)법을 이용하였으며 통계결과는 생물학적 통계분석에서 가장 많이 사용하는 유의차 5%( p <0.05)일 때 통계적 유의성이 있다고 간주하였다. For the evaluation results, the paired t-test method was used for changes before and after the use of the product, and the statistical results were statistically significant when the significant difference of 5% (p <0.05) used in the biological statistical analysis. Considered.
3) 설문 평가3) Survey evaluation
유효성 평가 설문 조사 결과와 제품 기호도 설문 조사 평가 결과를 근거로 평가하였다.The survey results and product preferences were also evaluated based on the survey results.
4) 통계 분석 프로그램은 SPSS version10.0 software를 이용하였다. 4) SPSS version 10.0 software was used for statistical analysis program.
(4) 결과(4) results
본 인체적용시험에 참여한 시험 대상자는 평균 연령 21.9±2.9인 20명의 건강한 성인 남·여 시험 대상자를 선정하여 실시하였으며 참여한 시험 대상자 20명이 중도탈락 없이 최종 시험을 완료하였다. The subjects who participated in this study were selected from 20 healthy adult male and female subjects with an average age of 21.9 ± 2.9. The 20 subjects completed the final test without dropping out.
1) 육안평가 결과1) Visual Evaluation
육안평가 결과 Global score를 통한 평가 등급은 일부 시험자의 경우는 moderate에서 mild로 감소하는 것을 확인할 수 있었으며, 전체 시험대상자의 Global score을 통한 평가 등급은 mild로 유의적인 변화는 없었다. As a result of visual evaluation, it was confirmed that the grade of global score decreased from moderate to mild in some test subjects, and the grade of global test score was mild.
한편, 시험 제품은 제품 사용 전(0일)과 비교하여 시험 제품 사용 1일 후, 제품 사용 3일 후, 제품 사용 5일 후에서 통계적으로 유의차가 있게 나타났다( p <0.05). On the other hand, the test product showed statistically significant difference after 1 day of test product use, 3 days after product use, and 5 days after product use compared to before product use (day 0).
평가 기간 동안 시험 제품에 의한 피부 유해사례는 발생하지 않았으며, 분석 결과는 다음 표 3과 같다.No adverse events occurred due to the test product during the evaluation period, and the analysis results are shown in Table 3 below.
측정 시점Measuring point 제품 사용 전(0일)Before using the product (0 days) 제품 사용 1일 후After 1 day of product use 제품 사용 3일 후After 3 days of product use 제품 사용 5일 후5 days after product use
GradeGrade MildMild MildMild MildMild MildMild
육안평가(평균±표준편차, 단위: Score)Visual evaluation (mean ± standard deviation, unit: score) 17.7±3.3 17.7 ± 3.3 16.3±4.0 16.3 ± 4.0 15.9±3.6 15.9 ± 3.6 15.4±4.2 15.4 ± 4.2
p-value p -value -- 0.005( p 〈 0.05)0.005 ( p <0.05) 0.012( p 〈 0.05)0.012 ( p <0.05) 0.003( p 〈 0.05)0.003 ( p <0.05)
2) 설문조사 결과2) Survey Results
a. 유효성 평가 설문조사 결과a. Effectiveness Survey Results
시험 제품 사용 후의 측정 항목에 대하여 실시한 설문 조사에 대한 결과는 다음 표 4와 같다.The results of the survey conducted on the measured items after using the test product are shown in Table 4 below.
시험 대상자 수(백분율, %)Number of test subjects (%) 평균Average 표준편차Standard Deviation
*5* 5 *4*4 *3* 3 *2*2 *1*One
여드름 개선 효과Acne improvement 6(30.0)6 (30.0) 14(70.0)14 (70.0) 0(0.0)0 (0.0) 0(0.0) 0 (0.0) 0(0.0)0 (0.0) 4.34.3 0.50.5
㈜ *5: 매우 만족, 4: 만족, 3: 보통, 2: 불만족, 1: 매우 불만족 * 5: very satisfied, 4: satisfied, 3: moderate, 2: dissatisfied, 1: very dissatisfied
설문 평가 결과, 여드름 개선 효과 항목에 대하여 시험 대상자의 100%가 만족 이상으로 평가하였다. As a result of the questionnaire evaluation, 100% of the test subjects rated the acne improvement effect items as more than satisfied.
b. 기호도 설문조사 결과b. Favorability Survey Results
제품 사용 후 제품의 만족도, 사용감, 사용 후 변화에 대하여 시험 대상자가 느끼는 기호도를 조사하였다. 조사 결과에 대한 결과는 다음 표 5와 같다.After using the product, the satisfaction level of the product, the feeling of use, and the degree of change after the use were examined. The results of the survey are shown in Table 5 below.
시험 대상자 수(백분율, %)Number of test subjects (%) 평균Average 표준편차Standard Deviation
*5* 5 *4*4 *3* 3 *2*2 *1*One
제품의 색Product color 12(60.0)12 (60.0) 7(35.0)7 (35.0) 1(5.0)1 (5.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.64.6 0.60.6
제품의 점도Product viscosity 12(60.0)12 (60.0) 7(35.0)7 (35.0) 1(5.0)1 (5.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.64.6 0.60.6
자극 정도Stimulation degree 6(30.0)6 (30.0) 9(45.0)9 (45.0) 5(25.0)5 (25.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.14.1 0.80.8
피부 흡수 정도Skin absorption degree 6(30.0)6 (30.0) 8(40.0)8 (40.0) 5(25.0)5 (25.0) 1(5.0)1 (5.0) 0(0.0)0 (0.0) 4.04.0 0.90.9
접착력Adhesion 6(30.0)6 (30.0) 7(35.0)7 (35.0) 6(30.0)6 (30.0) 1(5.0)1 (5.0) 0(0.0)0 (0.0) 3.93.9 0.90.9
부드러움Softness 5(25.0)5 (25.0) 12(60.0)12 (60.0) 3(15.0)3 (15.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.14.1 0.60.6
촉촉함Moist 7(35.0)7 (35.0) 6(30.0)6 (30.0) 7(35.0)7 (35.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.04.0 0.90.9
피지 개선 효과Sebum improvement effect 4(20.0)4 (20.0) 14(70.0)14 (70.0) 2(10.0)2 (10.0) 0(0.0)0 (0.0) 0(0.0)0 (0.0) 4.14.1 0.60.6
㈜ *5: 매우 만족, 4: 만족, 3: 보통, 2: 불만족, 1: 매우 불만족* 5: very satisfied, 4: satisfied, 3: moderate, 2: dissatisfied, 1: very dissatisfied
설문 평가 결과, 제품의 만족도 부분의 색, 점도 항목에 대하여 시험 대상자Results of the survey, subjects were tested for the color and viscosity of the satisfaction part of the product.
의 100%가 보통 이상으로 평가하였다. 사용감 부분에서는 자극 정도 항목에 대하여 시험 대상자의 100%가 보통 이상으로 평가하였고, 피부 흡수 정도, 접착력 항목에 대하여 시험 대상자의 95%가 보통 이상으로 평가하였다. 그리고 사용 후 변화 부분에서는 부드러움, 촉촉함, 피지 개선 효과 항목에 대하여 시험 대상자의 100%가 보통 이상으로 평가하였다. 100% of people rated above average. In terms of feeling, 100% of the test subjects rated above the average level for the stimulus level, and 95% of the test subjects rated above the average level for the skin absorption level and the adhesion level. In the post-use change part, 100% of the test subjects were evaluated to be above normal for the softness, moistness and sebum improvement effect items.
3) 피부자극평가3) Skin irritation evaluation
시험 대상자에 대한 피부자극평가(자가 평가) 결과는 다음 표 6과 같다. The skin irritation evaluation (self-evaluation) results of the test subjects are shown in Table 6 below.
홍반 (Erythema)Erythema 부종 (Edema)Edema 인셜 (Scaling)Scaling 가려움 (Itching) Itching 자통 (Stinging)Stinging 작열감 (Burning)Burning 뻣뻣함 (Tightness) Tightness 따끔거림 (Prickling)Prickling
사용 1일 후1 day after use 없음none 없음none 없음none 없음none 없음none 없음 none 없음none 없음none
사용 3일 후3 days after use 없음none 없음none 없음none 없음none 없음none 없음none 없음none 없음none
사용 5일 후5 days after use 없음none 없음none 없음none 없음none 없음none 없음none 없음none 없음none
시험 대상자들은 이상반응 발생 즉시 연구자에게 보고하도록 하였다. 또한 설문지를 통하여 피부 자극 여부에 표기하도록 하였다. 본 시험이 진행되는 동안 시험 대상자를 대상으로 한 설문 조사 결과, 시험 대상자 전원 시험 제품에 대한 피부 이상반응이 관찰되지 않았다. Subjects were advised to report to the investigator as soon as adverse events occurred. In addition, the questionnaire was to indicate whether the skin irritation. As a result of a survey of subjects during the trial, no skin adverse reactions were observed for all test subjects.
또한, 연구자에 의한 육안평가에 있어서도, 피부 이상반응은 관찰되지 않았다. In addition, in the visual evaluation by the researcher, no skin adverse reaction was observed.
4) 사진 촬영 결과4) Photo Shoot Results
시험 대상자들 모두에 대하여 사진 촬영을 진행하였으나, 여기에서는 모두 도시하지 않고 그 일부만을 도 17로 도시하였다. Photographs were taken for all the test subjects, but not all of them are shown in FIG. 17.
도 17로부터 시험 재료로 사용된 마그네슘 패치의 형상이나 부착의 형태에 대해 확인할 수 있고, 여드름 완화 효과의 육안관찰의 근거를 확인할 수 있음은 물론이다. From Fig. 17, it is possible to confirm the shape of the magnesium patch and the form of adhesion used as the test material, and of course, the basis of visual observation of the acne relief effect can be confirmed.
본 발명의 여드름 완화 및 예방용 마이크로 니들 및 마이크로 니들 패치에 대한 피부 자극평가 및 피부침습효과는 본 출원인에 의해 기 출원되어 공개된 한국공개특허 제2017-0115449호의 실험을 통해 규명한 바 있으며, 이로써 본 발명의 생체분해성 금속을 포함하는 패치는 정상세포나 조직에서 독성을 나타내지 않으면서 피부에 자극이 없이 침습하여 여드름 원인균에 대한 항균활성을 발현할 수 있음으로써, 간이하고 안전한 여드름 완화 및 예방에 기여할 수 있다.Skin irritation evaluation and skin invasion effect on the micro-needles and micro-needles patch for acne relief and prevention of the present invention has been identified through the experiment of Korean Patent Application No. 2017-0115449 published and published by the present applicant, thereby The patch containing the biodegradable metal of the present invention may invade without irritation on the skin without inducing toxicity in normal cells or tissues, thereby expressing antimicrobial activity against acne causing bacteria, thereby contributing to simple and safe acne relief and prevention. Can be.
한편, 이러한 생체적합성이 우수한 독성 없는 생체분해성 금속을 포함하는 패치의 선택적 항여드름균 활성 효과는, 반응식 1 내지 3에서 나타나는 금속의 분해 과정에서 발생하는 OH -이온으로 인한 국지적 pH의 증가가 중요 원인일 것으로 예측되며, 순수 마그네슘 또는 순수 아연 금속에 상기 화학식 1에 따른 성분들이 포함되어 분해속도가 가속화될 경우, 더욱 신속한 항균 효과가 기대된다.On the other hand, the selective anti-acne bactericidal activity of the patch containing the non-toxic biodegradable metal having excellent biocompatibility is mainly due to the increase of the local pH due to OH - ions generated during the decomposition of the metals shown in Schemes 1 to 3. It is expected that, if the pure magnesium or pure zinc metal containing the components according to the formula (1) to accelerate the decomposition rate, a faster antibacterial effect is expected.
본 발명의 생체분해성 금속을 적용한 패치는 별도의 약물의 담지없이 자체적으로 여드름 원인균에 대한 항균 활성을 가져 여드름 완화 및 예방용으로 유용하며, 이를 다양한 형태로 제작하여 피부에 적용하는 간이한 방법을 통해 여드름을 예방하거나 유발된 여드름에 대한 완화용 패치로서 유용할 수 있다.The patch to which the biodegradable metal of the present invention is applied is useful for alleviating and preventing acne by having antimicrobial activity against acne causing bacteria on its own without carrying a separate drug, and by using a simple method of applying it to the skin by manufacturing it in various forms It may be useful as a patch to prevent acne or to alleviate the caused acne.

Claims (13)

  1. 다음 화학식 1로 표시되고 항여드름 효과를 가지는 생체분해성 금속을 포함하는, 여드름 완화 및 예방용 패치. The following acne relief and prevention patch, comprising a biodegradable metal represented by the formula (1) having an anti-acne effect.
    [화학식 1][Formula 1]
    Mg aZn bX c Mg a Zn b X c
    화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, 0≤a≤100, 0≤b≤100, 0≤c≤10 범위 중 a 또는 b가 가장 크며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상임. In Formula 1, a, b, and c are weight percent of each component, and a + b + c = 100 wt%, and a or b is in a range of 0 ≦ a ≦ 100, 0 ≦ b ≦ 100, and 0 ≦ c ≦ 10. X is the one or more selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce and P.
  2. 제 1 항에 있어서, 상기 생체분해성 금속은 마이크로 니들 형태로 포함되는 것을 특징으로 하는 여드름 완화 및 예방용 패치. According to claim 1, wherein the biodegradable metal acne palliation and prevention patch, characterized in that included in the form of a microneedle.
  3. 제 1 항에 있어서, 상기 생체분해성 금속은 박판 형태로 포함되는 것을 특징으로 하는 여드름 완화 및 예방용 패치. According to claim 1, wherein the biodegradable metal acne palliation and prevention patch, characterized in that included in the form of a thin plate.
  4. 제 1 항에 있어서, 상기 화학식 1에서 a, b 및 c는 각 성분의 중량%로서, a+b+c=100중량%이고, i) 90≤a≤100, 0≤b≤10, 0≤c≤10 또는 ii) 0≤a≤10, 90≤b≤100, 0≤c≤10이며, X는 Ca, Fe, Mn, Si, Na, Zr, Ce 및 P로 구성된 군에서 선택되는 1종 이상인 것을 특징으로 하는 여드름 완화 및 예방용 패치.According to claim 1, wherein in Formula 1 a, b and c are the weight percentage of each component, a + b + c = 100% by weight, i) 90≤a≤100, 0≤b≤10, 0≤ c ≦ 10 or ii) 0 ≦ a ≦ 10, 90 ≦ b ≦ 100, 0 ≦ c ≦ 10, and X is one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P Acne relief and prevention patch, characterized in that above.
  5. 제 1 항에 있어서, 상기 생체분해성 금속은 불가피한 불순물을 포함한 순수 순도 95% 이상의 Mg인 것을 특징으로 하는 여드름 완화 및 예방용 패치.According to claim 1, wherein the biodegradable metal is a patch for acne alleviation and prevention, characterized in that the purity of 95% or more pure purity containing inevitable impurities.
  6. 제 1 항에 있어서, 상기 생체분해성 금속은 2 이상의 금속 상(phase)이 갈바닉 회로를 생성하여 분해속도가 가속화되는 것을 특징으로 하는 여드름 완화 및 예방용 패치.The patch of claim 1, wherein the biodegradable metal has two or more metal phases to generate a galvanic circuit to accelerate the decomposition rate.
  7. 제 6 항에 있어서, 상기 생체분해성 금속은 Mg 2Ca 상을 포함하는 것을 특징으로 하는 여드름 완화 및 예방용 패치.7. The patch of claim 6, wherein the biodegradable metal comprises a Mg 2 Ca phase.
  8. 제 6 항에 있어서, 상기 생체분해성 금속은 MgZn 상을 포함하는 것을 특징으로 하는 여드름 완화 및 예방용 패치.7. The patch of claim 6, wherein the biodegradable metal comprises a MgZn phase.
  9. 제 6 항에 있어서, 상기 생체분해성 금속은 Ca 2Mg 6Zn 3 상을 포함하는 것을 특징으로 하는 여드름 완화 및 예방용 패치.7. The patch of claim 6, wherein the biodegradable metal comprises a Ca 2 Mg 6 Zn 3 phase.
  10. 제 1 항에 있어서, 상기 생체분해성 금속은 금속 표면에 다른 종류의 제2의 금속이 코팅된 것을 특징으로 하는 여드름 완화 및 예방용 패치.The method of claim 1, wherein the biodegradable metal is a patch for acne relief and prevention, characterized in that the second surface of the metal is coated with a different type of metal.
  11. 제 10 항에 있어서, 상기 제2의 금속은 나트륨, 마그네슘, 칼륨, 철, 니켈, 아연, 갈륨, 셀레늄, 스트론튬, 지르코늄, 몰리브덴, 니오븀, 탄탈륨, 타이타늄, 규소, 은, 금, 망간 및 칼슘으로 구성된 군에서 선택되는 1종 이상의 금속인 것을 특징으로 하는 여드름 완화 및 예방용 패치.The method of claim 10, wherein the second metal is sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold, manganese and calcium. Acne relief and prevention patch, characterized in that at least one metal selected from the group consisting of.
  12. 제 1 항 내지 제 11항 중 어느 한 항의 여드름 완화 및 예방용 패치를 여드름 피부에 부착하여 사용하는 방법. Use of the acne alleviation and prevention patch of any one of claims 1 to 11 attached to the acne skin.
  13. 제 12 항에 있어서, 여드름 완화 및 예방용 패치를 여드름 피부에 부착하기전에 수분공급단계 또는 피부진정단계를 수행하는 것을 특징으로 하는 방법. 13. The method of claim 12, wherein the step of moisturizing or soothing the skin is performed prior to attaching the acne relief and prevention patch to the acne skin.
PCT/KR2019/006068 2018-05-21 2019-05-21 Patch for alleviation and prevention of acne WO2019225948A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR112020023541-5A BR112020023541B1 (en) 2018-05-21 2019-05-21 ADHESIVE FOR ACNE RELIEF AND PREVENTION
CN201980033618.9A CN112135609B (en) 2018-05-21 2019-05-21 Patch for alleviating and preventing acne
US17/057,103 US11679085B2 (en) 2018-05-21 2019-05-21 Patch for alleviation and prevention of acne
ES19807769T ES2966155T3 (en) 2018-05-21 2019-05-21 Acne Relief and Prevention Patch
EP19807769.5A EP3782615B1 (en) 2018-05-21 2019-05-21 Patch for alleviation and prevention of acne
JP2020564559A JP7317863B2 (en) 2018-05-21 2019-05-21 Patches for Acne Relief and Prevention

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180057629 2018-05-21
KR10-2018-0057629 2018-05-21
KR1020190058730A KR102310566B1 (en) 2018-05-21 2019-05-20 Patch for reducing and preventing acne
KR10-2019-0058730 2019-05-20

Publications (1)

Publication Number Publication Date
WO2019225948A1 true WO2019225948A1 (en) 2019-11-28

Family

ID=68617320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/006068 WO2019225948A1 (en) 2018-05-21 2019-05-21 Patch for alleviation and prevention of acne

Country Status (1)

Country Link
WO (1) WO2019225948A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116281A2 (en) * 2005-04-25 2006-11-02 Johnson & Johnson Consumer Companies, Inc. Method of treating acne with stratum corneum piercing device
KR20110065391A (en) * 2009-12-07 2011-06-15 유앤아이 주식회사 Drug delivery system using magnesium alloy
KR20120062243A (en) * 2010-12-06 2012-06-14 성균관대학교산학협력단 Degradability velocity control method of biodegradable magnesium and biodegradable magnesium using thereof
KR20150100227A (en) * 2014-02-25 2015-09-02 정은석 Compositions of dietary supplements for improvement of acne skin conditions
KR20150121053A (en) 2013-02-13 2015-10-28 히사미쓰 세이야꾸 가부시키가이샤 Microneedle coating composition and microneedle device
KR101622388B1 (en) 2015-10-21 2016-05-19 한국과학기술원 Silicon micro needle stamp and method of fabricating the same
KR20160058261A (en) 2014-11-14 2016-05-25 가천대학교 산학협력단 Manufacturing method for coating microneedle and the coating microneedle manufactured by the method
KR20170115449A (en) 2016-04-07 2017-10-17 랩앤피플주식회사 Micro needle Using the Bioabsorbable Metal
KR20180004202A (en) * 2015-06-17 2018-01-10 마가렛 진 프로펫 Topical and oral preparations containing taurine and magnesium to prevent and treat acne

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116281A2 (en) * 2005-04-25 2006-11-02 Johnson & Johnson Consumer Companies, Inc. Method of treating acne with stratum corneum piercing device
KR20110065391A (en) * 2009-12-07 2011-06-15 유앤아이 주식회사 Drug delivery system using magnesium alloy
KR20120062243A (en) * 2010-12-06 2012-06-14 성균관대학교산학협력단 Degradability velocity control method of biodegradable magnesium and biodegradable magnesium using thereof
KR20150121053A (en) 2013-02-13 2015-10-28 히사미쓰 세이야꾸 가부시키가이샤 Microneedle coating composition and microneedle device
KR20150100227A (en) * 2014-02-25 2015-09-02 정은석 Compositions of dietary supplements for improvement of acne skin conditions
KR20160058261A (en) 2014-11-14 2016-05-25 가천대학교 산학협력단 Manufacturing method for coating microneedle and the coating microneedle manufactured by the method
KR20180004202A (en) * 2015-06-17 2018-01-10 마가렛 진 프로펫 Topical and oral preparations containing taurine and magnesium to prevent and treat acne
KR101622388B1 (en) 2015-10-21 2016-05-19 한국과학기술원 Silicon micro needle stamp and method of fabricating the same
KR20170115449A (en) 2016-04-07 2017-10-17 랩앤피플주식회사 Micro needle Using the Bioabsorbable Metal

Similar Documents

Publication Publication Date Title
WO2020040442A1 (en) Soothing cream and preparation method therefor
WO2017176077A1 (en) Microneedle using biodegradable metal
EP0149872A2 (en) Cosmetic composition containing glycoproteins for the skin care
WO2017048028A1 (en) Novel antimicrobial peptide derived from myxinidin peptide, and use thereof
WO2017043670A1 (en) Cosmetic composition containing citron extract
WO2020218669A1 (en) Facial mask composition having improved moisturizing effect
WO2019225948A1 (en) Patch for alleviation and prevention of acne
WO2018143692A1 (en) Pharmaceutical composition including a powder of a ulmi cortex or ulmus davidiana root cortex as effective ingredient for wound treatment and skin regeneration
WO2020096379A1 (en) Hypoallergenic composition for skin regeneration or skin soothing, containing culture product or extract of aureobasidium pullulans strain
DE112015004182T5 (en) An antifungal composition comprising antimycotic peptide and terpene alcohol
WO2020218670A1 (en) Mask pack composition having improved wrinkle-reducing strength
WO2020180059A1 (en) Composition for producing melanin containing plasma activated medium and use thereof
WO2017119756A1 (en) Wrinkle-improving, anti-aging, whitening, anti-inflammatory functional novel peptide, and composition containing same
WO2018128212A1 (en) Male contraceptive tool filled with gel-type coating agent
KR20190132937A (en) Patch for reducing and preventing acne
WO2017099329A1 (en) Deodorizing cosmetic composition and method for preparing same
WO2020197016A1 (en) Novel antimicrobial peptide derived from pseudin-2 peptide, and use thereof
WO2022191602A1 (en) Cosmetic composition comprising carnitine-salicylate as active ingredient
WO2019031790A1 (en) External-use skin preparation composition, containing ceramide, derivative thereof and hisbiscior cortex extract
WO2020189944A1 (en) Flexible metal patch having antioxidant activity and whitening effect and method for using same
WO2022139558A1 (en) Composition for protecting the skin against harmful substance, light and stress
WO2021107381A1 (en) Composition comprising ferulic acid and analogs thereof for preventing and treating skin diseases caused by genetic mutation
WO2023243900A1 (en) Acne relief and prevention patch with excellent skin adhesion
WO2020060277A1 (en) Composition for preventing or treating oral diseases or bone diseases
EA009549B1 (en) Barrier formulation, method for its manufacture and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807769

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020564559

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019807769

Country of ref document: EP

Effective date: 20201118

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020023541

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020023541

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201118